Antibody Bank
(Kato's Lab; Tohoku University)
mAb list (target)
ACKR1/ ACKR2/ ACKR3/ ACKR4/ ACKR5/ ATRX/ BAPtag/ CA4/ CART (CD19/ GPC3/ HER2/ PDPN/ PODXL)/ CasMab (PDPN/ PODXL/ CD44s/ CD44v6/ EpCAM/ TROP2/ EGFR/ HER2/ HER3)/ cat protein (cMET/ cPDPN)/ CCR1/ CCR2/ CCR3/ CCR4/ CCR5/ CCR6/ CCR7/ CCR8/ CCR9/ CCR10/ CD10/ CD19/ CD20 (rituximab; obinutuzumab; ofatumumab)/ CD39/ CD44s/ CD44v3/ CD44v4/ CD44v5/ CD44v6 (bivatuzumab)/ CD44v7/ CD44v8/ CD44v9/ CD44v10/ CD73/ CD133/ CD271/ CD273/ CD274/ CD276/ CDH1/ CDH2/ CDH3/ CDH4/ CDH5/ CDH6/ CDH7/ CDH8/ CDH9/ CDH10/ CDH11/ CDH12/ CDH13/ CDH15/ CDH16/ CDH17/ CDH18/ CDH19/ CDH20/ CDH21/ CDH22/ CDH23/ CDH24/ CDH25/ CXCR1/ CXCR2/ CXCR3/ CXCR4/ CXCR5/ CXCR6/ CXCR7/ CX3CR1/ DGK/ dog protein (dPDPN/ dHER2/ dEGFR/ dPD-L1)/ EGFR (cetuximab; panitumumab)/ EpCAM/ EphA1/ EphA2/ EphA3/ EphA4/ EphA5/ EphA6/ EphA7/ EphA8/ EphA10/ EphB1/ EphB2/ EphB3/ EphB4/ EphB6/ GM3/ GPC1/ GPC2/ GPC3/ GPC4/ GPC5/ GPC6/ HER2 (pertuzumab; trastuzumab)/ HER3 (patritumab)/ HER4/ HGF/ Histag/ IDH/ isotype control/ KLRG1/ LPtag/ MAPtag/ MBPtag/ mCasMab (mEGFR/ mHER2)/ Mpox/ PAtag/ PD-L1/ PD-L2/ PODXL/ PDPN (mouse; rat; rabbit; dog; bovine; cat; tiger; horse; pig; goat; alpaca; Tas_devil; bear; whale; sheep; sea_lion; elephant; ferret; hamster; giraffe; panda; rhino; hippo)/ RAPtag/ RdRP/ RIEDLtag/ SARS-CoV-2 (N/ S2/ bispecific/ bebtelovimab; cilgavimab; casirivimab; bamlanivimab)/ TERT/ TIGIT/ TROP2 (datopotamab; sacituzumab)/ XCR1
--> company (clone)ACKR1/ ACKR2/ ACKR3/ ACKR4/ ACKR5/ ATRX/ BAPtag/ CA4/ CART (CD19/ GPC3/ HER2/ PDPN/ PODXL)/ CasMab (PDPN/ PODXL/ CD44s/ CD44v6/ EpCAM/ TROP2/ EGFR/ HER2/ HER3)/ cat protein (cMET/ cPDPN)/ CCR1/ CCR2/ CCR3/ CCR4/ CCR5/ CCR6/ CCR7/ CCR8/ CCR9/ CCR10/ CD10/ CD19/ CD20 (rituximab; obinutuzumab; ofatumumab)/ CD39/ CD44s/ CD44v3/ CD44v4/ CD44v5/ CD44v6 (bivatuzumab)/ CD44v7/ CD44v8/ CD44v9/ CD44v10/ CD73/ CD133/ CD271/ CD273/ CD274/ CD276/ CDH1/ CDH2/ CDH3/ CDH4/ CDH5/ CDH6/ CDH7/ CDH8/ CDH9/ CDH10/ CDH11/ CDH12/ CDH13/ CDH15/ CDH16/ CDH17/ CDH18/ CDH19/ CDH20/ CDH21/ CDH22/ CDH23/ CDH24/ CDH25/ CXCR1/ CXCR2/ CXCR3/ CXCR4/ CXCR5/ CXCR6/ CXCR7/ CX3CR1/ DGK/ dog protein (dPDPN/ dHER2/ dEGFR/ dPD-L1)/ EGFR (cetuximab; panitumumab)/ EpCAM/ EphA1/ EphA2/ EphA3/ EphA4/ EphA5/ EphA6/ EphA7/ EphA8/ EphA10/ EphB1/ EphB2/ EphB3/ EphB4/ EphB6/ GM3/ GPC1/ GPC2/ GPC3/ GPC4/ GPC5/ GPC6/ HER2 (pertuzumab; trastuzumab)/ HER3 (patritumab)/ HER4/ HGF/ Histag/ IDH/ isotype control/ KLRG1/ LPtag/ MAPtag/ MBPtag/ mCasMab (mEGFR/ mHER2)/ Mpox/ PAtag/ PD-L1/ PD-L2/ PODXL/ PDPN (mouse; rat; rabbit; dog; bovine; cat; tiger; horse; pig; goat; alpaca; Tas_devil; bear; whale; sheep; sea_lion; elephant; ferret; hamster; giraffe; panda; rhino; hippo)/ RAPtag/ RdRP/ RIEDLtag/ SARS-CoV-2 (N/ S2/ bispecific/ bebtelovimab; cilgavimab; casirivimab; bamlanivimab)/ TERT/ TIGIT/ TROP2 (datopotamab; sacituzumab)/ XCR1
--> Kato' lab in Tohoku University Graduate School of Medicine
--> YouTube
Peptide tag system
| PA tag NZ-1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PA tag mAb NZ-1; rat IgG2a, lambda |
PAtag: GVAMPGAEDDVV; 12 amino acid; trademark: No. 5671624; ref: Nature; Nature; Commu biol | Purification, IP, IHC, WB, FACS | PEP2014;
JCS2016 PS2019; AC2021 Sci2022 |
done |
APRO wako |
| anti-PA tag mAb NZ-27; human IgG1, lambda |
PAtag: GVAMPGAEDDVV; 12 amino acid; trademark: No. 5671624; from AMED_PDIS project | Purification, IP, IHC, WB, FACS | JBC2023 | done |
|
| anti-PA14 tag mAb NZ-1; rat IgG2a, lambda |
PA14 tag: EGGVAMPGAEDDVV; from AMED_SentanBio | Purification, IP, IHC, WB, FACS |
PA14 tag system hGH-fusion Fab |
done |
APRO |
| anti-PA16 tag mAb NZ-1; rat IgG2a, lambda |
PA16 tag: GLEGGVAMPGAEDDVV; from AMED_SentanBio | Purification, IP, IHC, WB, FACS | C44Mab5; PMab202; PMab210; PMab213; PMab219; PMab233 | done | APRO |
| MAP tag PMab-1 | Character | Application | Ref | Gene cloning | Company |
| anti-MAP tag mAb PMab-1: rat IgG2a, kappa--> PAtag |
MAPtag (GDGMVPPGIEDK; 12 amino acids); trademark: No. 5988384; from AMED_KakushinBio; press release | Purification, IP, IHC, WB, FACS | MAB2016 BBREP2018 JB2020 |
done | APRO; AA; abcam; Nov; Merck; BL |
| anti-MAP16 tag mAb (PMab-1; rat IgG2a, kappa) |
MAP16 tag: PGTGDGMVPPGIEDKI; 16 amino acids; from AMED_Tousa | Purification, IP, IHC, WB, FACS | PMab-235
PMab-44_goat |
done | |
| RAP tag PMab-2 | Character | Application | Ref | Gene cloning | Company |
| anti-RAP tag mAb (PMab-2; mouse IgG1, kappa)--> PAtag |
RAP tag: DMVNPGLEDRIE; 12 amino acids; from AMED_KakushinBio | Purification, IP, IHC, WB, FACS | MAB2017 FPS2020 PP2021 |
done |
APRO;
AA;
abcam Merck; BL |
| anti-RAP14 tag mAb (double tag) (PMab-2; LpMab-7) |
RAP14 tag (DMVNPGLEDRIEDL; 14 amino acids); from AMED_Tousa | Purification, IP, IHC, WB, FACS | PMab44; PMab256; PDF; PMab253 | done | |
| anti-RAP16 tag mAb (PMab-2; mouse IgG1, kappa) |
RAP16 (GPGDDMVNPGLEDRIE; 16 amino acids); from AMED_SentanBio | Purification, IP, IHC, WB, FACS | PMab-225_alpaca
PMab-225_epitope PMab-44_alpaca |
done | |
| RIEDL tag LpMab-7 | Character | Application | Ref | Gene cloning | Company |
| anti-RIEDL tagmAb (LpMab-7; mouse IgG1, kappa)-->PAtag |
RIEDLtag (RIEDL; 5 amino acids): from AMED_SentanBio | Purification, IP, IHC, WB, FACS | RIEDL; PMab237 (1); PMab237 (2); C44-5; C44-46; E134; E51 | done | abcam |
| MBP tag TMab-2 | Character | Application | Ref | Gene cloning | Company |
| anti-MBP tag mAb (TMab-2; rat IgG2b, kappa) |
specific for maltose-binding protein | IHC, WB | PubMed
|
done |
APRO |
| anti-MBP tag mAb (YM-2;rat IgG2b, kappa) |
specific for maltose-binding protein | IHC, WB | PubMed
|
done | BioLegend |
| BAP tag PMab-44 | Character | Application | Ref | Gene cloning | Company |
| anti-BAP tagmAb (PMab-44; mouse IgG1, kappa)--> PAtag |
BAP tag(EKTTLGVEDYTTTPAA; 16 amino acids); from AMED_BINDS_SentanBio | Purification, IP, IHC, WB, FACS | PMab247 PMab241 |
done |
APRO Zenogen |
| LP tag LpMab-17 | Character | Application | Ref | Gene cloning | Company |
| anti-LP tag mAb (LpMab-17; mouse IgG1, kappa)-->PAtag |
LPtag (NSVTGIRIEDLPTSES; 16 amino acids); from AMED_BINDS_SentanBio | Purification, IP, IHC, WB, FACS | PMab52 PMab231 |
done |
BD Merck |
| His tag HisMab-1 | Character | Application | Ref | Gene cloning | Company |
| anti-His tag (HisMab-1;mouse IgG2b, kappa)-->PAtag | His tag (HHHH; 4 amino acids); from AMED_SentanBio; Kd: 4.4 x 10^-9 M | Purification, IP, IHC, WB, FACS |
C20Mab60 Rituximab C20Mab11 |
done | APRO |
| anti-His tag (HisMab-1-hG1; human IgG1, kappa) | His tag (HHHH; 4 amino acids); from AMED_SentanBio | Purification, IP, IHC, WB, FACS | done | ||
| anti-His tag (HisMab-1-scFv-mG2a; mouse IgG2a) | scFv of HisMab-1; Kd: 6.6 x 10^-9 M | IHC, WB, FACS | done |
Isotype control
| antibody (mouse) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-SARS-CoV-2 mAb (CvMab-62; mouse IgG1, kappa) | specific for SARS-CoV-2 S2 | ELISA isotype control of mouse IgG1 |
CvMab-62 | done | |
| anti-tiger PDPN mAb (PMab-231-f; mouse IgG2a, kappa) | defucosylation of PMab-231 | isotype control of mouse IgG2a in vivo |
250_in vivo | done | zenogen |
| anti-hamPDPN mAb (281-mG2a-f; mouse IgG2a, kappa) | defucocylated 281-mG2a | isotype control of mouse IgG2a in vivo |
H2Mab-214 H2Mab-77 |
done | |
| anti-RdRP mAb (RdMab-20; mouse IgG2b, kappa) | specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP | ELISA, WB isotype control of mouse IgG2b |
RdMab-20 | done | |
| anti-RdRP mAb (RdMab-13; mouse IgM, kappa) | specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP | ELISA, WB isotype control of mouse IgM |
RdMab-13 | done | |
| antibody (rat) | Character | Application | Ref | Gene cloning | Company |
| anti-mTERT mAb (TmMab-1; rat IgG1, kappa) | specific for mTERT | ELISA, WB isotype control of rat IgG1 |
done | ||
| anti-mTERT mAb (TmMab-3; rat IgG1, kappa) |
specific for mTERT | ELISA, WB isotype control of rat IgG1 |
done | ||
| anti-mTERT mAb (TmMab-4; rat IgG1, kappa) |
specific for mTERT | ELISA isotype control of rat IgG1 |
done | ||
| anti-mTERT mAb (TmMab-2; rat IgG2a, kappa) | specific for mTERT | ELISA isotype control of rat IgG2a |
done | ||
| anti-IDH1 mAb(RcMab-1; rat IgG2a, kappa) | specific for IDH1 | IHC, WB isotype control of rat IgG2a |
RcMab-1 | done |
abcam CST MBL |
| anti-IDH2-R172K mAb (KMab-1; rat IgG2b, kappa) | specific for IDH2-R172K | IHC, WB isotype control of rat IgG2b |
KMab-1 | done | abcam MBL |
| antibody (human) | Character | Application | Ref | Gene cloning | Company |
| anti-SARS-CoV-2 mAb (humCvMab-62; human IgG1, kappa) | specific for SARS-CoV-2 S2 | ELISA isotype control of human IgG1 |
done |
Chemokine receptor (summary)
| mouse CCR1 (CD191) | Character --> anti-human CCR1 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR1 mAb (C1Mab-1; rat IgG2b, lambda) | CBIS method; Kd: 1.5 x 10^-8 M ref: clone S15040E (BioLegend); rat IgG2b; Kd: 3.5 x 10^-8 M; no mAb from BD (summary) |
FACS, WB | done | ||
| anti-mouse CCR1 mAb (C1Mab-2; rat IgG2b, lambda) | CBIS method Kd: 3.9 x 10^-9 M |
FACS, WB | done | ||
| anti-mouse CCR1 mAb (C1Mab-5; rat IgG2b, lambda) | CBIS method Kd: 1.2 x 10^-8 M |
FACS, WB | done | ||
| anti-mouse CCR1 mAb (C1Mab-6; rat IgG2b, kappa) | CBIS method Kd: 3.9 x 10^-9 M |
FACS, WB | C1Mab-6 | done |
| mouse CCR2 (CD192) | Character --> anti-human CCR2 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR2 mAb (C2Mab-6; rat IgG1, kappa) |
ref: clone EPR20844-15 (abcam); rabbit IgG
ref: clone 475301 (BD); rat IgG2b ref: clone SA203G11 (BioLegend); rat IgG2b |
FACS, WB, ICC |
C2Mab-6 epitope (summary) |
done | BD |
| mouse CCR3 (CD193) | Character --> anti-human CCR3 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR3 mAb(C3Mab-2; rat IgG2b, kappa) |
specific for mouse CCR3; established by CBIS method (summary) | FACS |
C3Mab-2 ICC |
done | |
| anti-mouse CCR3 mAb (C3Mab-3; rat IgG2a, kappa0 | specifc mouse CCR3; established by CBIS method | FACS |
C3Mab-3 epitope |
done | |
| anti-mouse CCR3 mAb (C3Mab-4; rat IgG2a, kappa) | specific mouse CCR3; established by CBIS method | FACS | epitope | done | |
| anti-mouse CCR3 mAb (C3Mab-6; rat IgG1, kappa) | specific mouse CCR3; peptide immunization | FACS |
C3Mab-6 epitope |
done | |
| anti-mouse CCR3 mAb (C3Mab-7; rat IgG1, kappa) | specific mouse CCR3; peptide immunization | FACS |
C3Mab-7 epitope-1 epitope-2 |
done |
| mouse CCR4 (CD194) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR4 mAb (C4Mab-1; rat IgG1, kappa) | specific for mouse CCR4; peptide immunization
2G12 (BioLegend); hamster IgG no mAb from BD (summary) |
FACS |
C4Mab-1 epitope |
done | |
| anti-mouse CCR4 mAb (C4Mab-1-mG2a-f; mIgG2a,k) | specific for mouse CCR4 | FACS | done |
| mouse CCR5 (CD195) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR5 mAb (C5Mab-1; rat IgM, kappa) | specific for CCR5 (by CBIS method) ; ref: clone C34-3448 (BD); rat IgG2c; ref: clone HM-CCR5 (BioLegend); hamster (Kd: 1.6 x 10^-7) (summary) | FACS | done | ||
| anti-mouse CCR5 mAb (C5Mab-2; rat IgG2b, kappa) | specific for CCR5 by CBIS method (Kd: 4.3 x 10^-8) |
FACS | C5Mab-2 | done | |
| anti-mouse CCR5 mAb (C5Mab-3; rat IgG2b, kappa) | specific for CCR5 by CBIS method (Kd: 5.8 x 10^-8) |
FACS | done | ||
| anti-mouse CCR5 mAb (C5Mab-4; rat IgG2a, kappa) | specific for CCR5 by peptide immunization (Kd: 3.5 x 10^-8) immunogen: MDFQGSVPTYSYDIDYGMS |
FACS, WB | C5Mab-4 | done | |
| anti-mouse CCR5 mAb (C5Mab-5; rat IgG2a, kappa) | specific for CCR5 by peptide immunization (Kd: 8.1 x 10^-8) immunogen: MDFQGSVPTYSYDIDYGMS |
FACS, WB | done | ||
| anti-mouse CCR5 mAb (C5Mab-7; rat IgG1, kappa) | specific for CCR5 by peptide immunization immunogen: MDFQGSVPTYSYDIDYGMS |
FACS | done | ||
| anti-mouse CCR5 mAb (C5Mab-8; rat IgG1, kappa) | specific for CCR5 by peptide immunization (Kd: 7.3 x 10^-9) immunogen: MDFQGSVPTYSYDIDYGMS |
FACS, WB | C5Mab-8 | done |
| mouse CCR6 (CD196) | Character --> anti-human CCR6 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR6 mAb (C6Mab-9; rat IgG1, kappa) |
peptide immunization immunogen: MNSTESYFGTDDYDNTEYY (summary) |
FACS | done | BD | |
| anti-mouse CCR6 mAb (C6Mab-9-mG2a-f; mIgG2a,k) | mouse IgG2a type of C6Mab-9 ref: clone 29-2L17 (BioLegend); hamster IgG ref: clone 140706 (BD); rat IgG2a |
FACS | done | ||
| anti-mouse CCR6 mAb (C6Mab-10; rat IgG2a, kappa) | peptide immunization immunogen: MNSTESYFGTDDYDNTEYY |
FACS, WB | done | ||
| anti-mouse CCR6 mAb (C6Mab-13; rat IgG1, kappa) | peptide immunization immunogen: MNSTESYFGTDDYDNTEYY |
FACS |
C6Mab-13 epitope |
done |
| mouse CCR7 (CD197) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR7 mAb (C7Mab-2, rat IgG2b, kappa) | specific for mouse CCR7; ref: clone: 4B12 (Biolegend) | FACS | |||
| anti-mouse CCR7 mAb (C7Mab-4, rat IgG2a, kappa) | specific for mouse CCR7 | FACS | |||
| anti-mouse CCR7 mAb (C7Mab-5, rat IgM, kappa) | specific for mouse CCR7 | FACS | |||
| anti-mouse CCR7 mAb (C7Mab-6, rat IgM, kappa) | specific for mouse CCR7 | FACS | |||
| anti-mouse CCR7 mAb (C7Mab-7, rat IgG1, kappa) | specific for mouse CCR7 | FACS, WB | C7Mab-7 | done | |
| anti-mouse CCR7 mAb (C7Mab-8, rat IgG2a, lambda) | specific for mouse CCR7 | FACS | |||
| anti-mouse CCR7 mAb (C7Mab-9, rat IgM, kappa) | specific for mouse CCR7 | FACS | |||
| anti-mouse CCR7 mAb (C7Mab-10, rat Ig) | specific for mouse CCR7 | FACS | |||
| anti-mouse CCR7 mAb (C7Mab-11, rat IgG1, kappa) | specific for mouse CCR7 | FACS, WB(weak) | |||
| anti-mouse CCR7 mAb (C7Mab-12, rat IgG2a, lambda) | specific for mouse CCR7 | FACS | |||
| anti-mouse CCR7 mAb (C7Mab-13, rat IgM, kappa) | specific for mouse CCR7 | FACS | |||
| anti-mouse CCR7 mAb (C7Mab-14, rat IgG1, kappa) | specific for mouse CCR7 | FACS | |||
| anti-mouse CCR7 mAb (C7Mab-15, rat IgG1, kappa) | specific for mouse CCR7 | FACS, WB(weak) |
| mouse CCR8 (CD198) | Character --> anti-human CCR8 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR8 mAb (C8Mab-1; rat IgG2a, kappa) |
clone SA214G2 (BioLegend); rat IgG2b no mAb from BD patent (Shionogi/Osaka Univ.) (summary) |
FACS, ICC | C8Mab-1 | done | |
| anti-mouse CCR8 mAb (C8Mab-2; rat IgG2b, kappa) |
specific mouse CCR8 established by CBIS method |
FACS, ICC |
C8Mab-2 ICC epitope |
done | Merck |
| anti-mouse CCR8 mAb (C8Mab-2-mG2a) | mouse IgG2a type of C8Mab-2 established by CBIS method |
FACS, ICC | done |
|
|
| anti-mouse CCR8 mAb (C8Mab-3; rat IgG1, kappa) |
specific mouse CCR8 established by CBIS method |
FACS, ICC | C8Mab-3 | done |
| mouse CCR9 (CD199) | Character --> anti-human CCR9 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR9 mAb (C9Mab-24; rat IgG2a, kappa) | immunogen: MMPTELTSLIPGMFDDFSYC (summary) ref: clone 9B1 (BioLegend; BD); rat IgG2a ref: clone CW-1.2 (BioLegend; BD); mouse IgG2a |
FACS, WB |
C9Mab-24 epitope |
done |
| mouse CCR10 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR10 mAb (CC10Mab-1; rat IgM, kappa) | CBIS method
(summary) ref: clone 248918R (R&D); rat IgG2a |
FACS | in preparation (Li et al) |
| mouse CXCR1 (CD181) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CXCR1 mAb (Cx1Mab-1; rat IgG1, kappa) | by CBIS; Kd: 2.6 x 10^-9 M (summary) ref: clone 1122A (R&D); rabbit IgG; Kd: 2.7 x 10^-9 M; clone U45-632 (BD); rat IgG2b |
FACS, WB | Cx1Mab-1 | done | |
| anti-mouse CXCR1 mAb (Cx1Mab-2; rat IgG1, kappa) | Kd: 2.0 x 10^-9 M
immunogen: MAEAEYFIWTNPEGDFEKE |
FACS WB (weak) |
|||
| anti-mouse CXCR1 mAb (Cx1Mab-3; rat IgG2a, kappa) | Kd: 6.2 x 10^-10 M immunogen: MAEAEYFIWTNPEGDFEKE |
FACS WB (weak) |
|||
| anti-mouse CXCR1 mAb (Cx1Mab-4; rat IgG1, kappa) | Kd: 2.1 x 10^-9 M immunogen: MAEAEYFIWTNPEGDFEKE |
FACS | |||
| anti-mouse CXCR1 mAb (Cx1Mab-5; rat IgG2a, kappa) | Kd: 8.2 x 10^-9 M immunogen: MAEAEYFIWTNPEGDFEKE |
FACS, WB | |||
| anti-mouse CXCR1 mAb (Cx1Mab-6; rat IgG1, kappa) | Kd: 1.0 x 10^-9 M immunogen: MAEAEYFIWTNPEGDFEKE |
FACS | |||
| anti-mouse CXCR1 mAb (Cx1Mab-7; rat Ig2b, kappa) | Kd: 8.1 x 10^-9 M immunogen: MAEAEYFIWTNPEGDFEKE |
FACS | |||
| anti-mouse CXCR1 mAb (Cx1Mab-8; rat Ig2b, kappa) | Kd: 3.0 x 10^-10 M immunogen: MAEAEYFIWTNPEGDFEKE |
FACS | Cx1Mab-8 |
| mouse CXCR2 (CD182) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CXCR2 mAb (Cx2Mab-1; rat IgG2b, kappa) | immunogen: MGEFKVDKFNIEDFFSGDL; Kd: 9.4 x 10^-9 M; ref: SA045E1 (BioLegend; Kd: 1.6 x 10^-8 M) | FACS | in preparation (Kaneko et al) | done | |
| anti-mouse CXCR2 mAb (Cx2Mab-2; rat IgG2b, kappa) | immunogen: MGEFKVDKFNIEDFFSGDL Kd: 1.0 x 10^-8 M (summary) |
FACS | done | ||
| anti-mouse CXCR2 mAb (Cx2Mab-3; rat Ig) | specific for mouse CXCR2; by CBIS method | FACS | in preparation (Kobayashi et al) | ||
| anti-mouse CXCR2 mAb (Cx2Mab-4; rat Ig) | specific for mouse CXCR2; by CBIS method | FACS |
| mouse CXCR3 (CD183) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CXCR3 mAb (Cx3Mab-2; rat IgG2b, kappa) | immunogen: MYLEVSERQVLDASDFAFL (summary) Kd: 5.9 x 10^-9 M; ref: clone: CXCR3-173 (BD; BioLegend); hamster IgG; Kd: 1.3 x 10^-9 M |
FACS | done | ||
| anti-mouse CXCR3 mAb (Cx3Mab-4; rat IgG1, kappa) | immunogen: MYLEVSERQVLDASDFAFL Kd: 1.3 x 10^-9 M |
FACS | Cx3Mab-4 | done | |
| anti-mouse CXCR3 mAb (Cx3Mab-5; rat IgG2c, kappa) | immunogen: MYLEVSERQVLDASDFAFL Kd: 5.3 x 10^-9 M |
FACS | done | ||
| anti-mouse CXCR3 mAb (Cx3Mab-6; rat IgG2b, kappa) | immunogen: MYLEVSERQVLDASDFAFL Kd: 4.5 x 10^-9 M |
FACS | done |
| mouse CXCR4 (CD184) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CXCR4 mAb (Cx4Mab-1; rat IgG2a, kappa) | by CBIS method; Kd: 6.4 x 10^-9 M; ref: clone 2B11/CXCR4 (BD), rat IgG2b; ref: clone
L276F12 (BioLegend), rat IgG2b (summary)
|
FACS | Cx4Mab-1 | done | |
| anti-mouse CXCR4 mAb (Cx4Mab-2; rat IgG2b, kappa) | specific for mouse CXCR4 immunogen: MEPISVSIYTSDNYSEEVG; Kd: 3.0 x 10^-7 M |
FACS, WB | in preparation (Yamamoto et al) | ||
| anti-mouse CXCR4 mAb (Cx4Mab-3; rat IgG2b, kappa) | specific for mouse CXCR4 immunogen: MEPISVSIYTSDNYSEEVG |
FACS | |||
| anti-mouse CXCR4 mAb (Cx4Mab-4; rat IgG2b, kappa) | specific for mouse CXCR4 immunogen: MEPISVSIYTSDNYSEEVG; Kd: 5.5 x 10^-7 M |
FACS, WB | |||
| anti-mouse CXCR4 mAb (Cx4Mab-5; rat IgG2b, kappa) | specific for mouse CXCR4 immunogen: MEPISVSIYTSDNYSEEVG |
FACS |
| mouse CXCR5 (CD185) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CXCR5 mAb (Cx5Mab-2; rat IgG2a, kappa) | immunogen: MNYPLTLDMGSITYNMDDL Kd: 7.0 x 10^-9; ref: clone 2G8 (BD) ; ref: clone L138D7 (BioLegend) (summary) |
FACS | done | ||
| anti-mouse CXCR5 mAb (Cx5Mab-3; IgG2b, kappa) | specific for mouse CXCR5; immunogen: MNYPLTLDMGSITYNMDDL Kd: 7.2 x 10^-10 |
FACS | Cx5Mab-3 | done | |
| anti-mouse CXCR5 mAb (Cx5Mab-4; IgM, kappa) | specific for mouse CXCR5; immunogen: MNYPLTLDMGSITYNMDDL |
FACS | done |
| mouse CXCR6 (CD186) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CXCR6 mAb(Cx6Mab-1; rat IgG1, kappa) | specific for mouse CXCR6; immunogen: MDDGHQESALYDGHYEGDF (summary) |
FACS, WB |
Cx6Mab-1 epitope-1 epitope-2 |
done | BD |
| anti-mouse CXCR6 mAb(Cx6Mab-5; rat IgG1, kappa) | specific for mouse CXCR6; immunogen: MDDGHQESALYDGHYEGDF | FACS, WB | done |
| mouse CX3CR1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CX3CR1 mAb (X3Mab-1; rat IgG1, kappa) | immunogen: MSTSFPELDLENFEYDDSA ref: clone SA011F11 (BioLgend): mouse IgG2a; ref: clone Z8-50 (BD): rat IgG2a |
FACS (weak), WB (weak) | |||
| anti-mouse CX3CR1 mAb (X3Mab-2; rat IgG1, kappa) | specific for mouse CX3CR1 immunogen: MSTSFPELDLENFEYDDSA |
FACS (weak), WB (weak) |
| mouse ACKR1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse ACKR1 mAb (A1Mab-1, rat IgM, kappa) | specific for ACKR1 ref no p.c. mAbs |
FACS | Ishikawa et al |
| mouse ACKR2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse ACKR2 mAb (A2Mab series) | specific for ACKR2 | FACS |
| mouse ACKR3 (CD187, CXCR7) | Character (summary) | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse ACKR3 mAb (A3Mab-1; rat IgG2a, kappa) | specific for mouse ACKR3; immunogen: MDVHLFDYAEPGNYSDINW; ref: 8F11-M1 (BioLegend; Kd: 8.3 x 10^-8 M) | FACS | done | ||
| anti-mouse ACKR3 mAb (A3Mab-2; rat IgG2a, kappa) | specific for mouse ACKR3; Kd: 1.5 x 10^-8 M | FACS, WB | |||
| anti-mouse ACKR3 mAb (A3Mab-3; rat IgG2a, kappa) | specific for mouse ACKR3; Kd: 2.0 x 10^-8 M | FACS, WB | |||
| anti-mouse ACKR3 mAb (A3Mab-4; rat IgG2a, kappa | specific for mouse ACKR3 | FACS | |||
| anti-mouse ACKR3 mAb (A3Mab-5; rat IgG2a, kappa) | specific for mouse ACKR3; Kd: 2.6 x 10^-9 M | FACS | |||
| anti-mouse ACKR3 mAb (A3Mab-6; rat IgG2a, kappa) | specific for mouse ACKR3; Kd: 1.9 x 10^-8 M | FACS, WB | |||
| anti-mouse ACKR3 mAb (A3Mab-7; rat IgG2a, kappa) | specific for mouse ACKR3; Kd: 1.5 x 10^-8 M | FACS, WB | in preparation (Yamamoto et al) | ongoing | |
| anti-mouse ACKR3 mAb (A3Mab-8; rat IgG2a, kappa) | specific for mouse ACKR3; Kd: 1.9 x 10^-8 M | FACS |
| mouse ACKR4 (CCR11, CCRL1) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse ACKR4 mAb (A4Mab-1; rat IgG2b, kappa) |
immunogen: MALELNQSAEYYYEENEMN; Kd: 3.5 x 10^-9 no commercially available mAb |
FACS, WB(weak) | A4Mab-1 | done | |
| anti-mouse ACKR4 mAb (A4Mab-2; rat IgG2b, kappa) |
immunogen: MALELNQSAEYYYEENEMN
Kd: 6.1 x 10^-9 |
FACS, WB | A4Mab-2 | done | |
| anti-mouse ACKR4 mAb (A4Mab-3; rat IgG2b, kappa) |
immunogen: MALELNQSAEYYYEENEMN
Kd: 1.6 x 10^-9 |
FACS | A4Mab-3 | done |
| mouse ACKR5 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse ACKR5 mAb (A5Mab-1, mouse Ig) | also known as CCRL2 ref: clone S21013E (BioLegend) |
FACS | Ishikawa et al |
| mouse XCR1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mXCR1 mAb | in preparation | FACS |
| human CCR1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR1 mAb |
in preparation |
| human CCR2 (CD192) | Character --> anti-mouse CCR2 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR2 mAb (C2Mab-9; mouse IgG1, kappa) |
specific for human CCR2; expressed in U937 or NK cell; peptide immunization | FACS, ICC |
C2Mab-9 epitope |
done |
| human CCR3 | Character --> anti-mouse CCR3 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR3 mAb (C3Mab-8; mouse IgG1, kappa)
|
specific for human CCR3 peptide immunization; Kd: 5.0 x 10^-9 M ref: 5E8 (BioLegend); Kd: 2.5 x 10^-9 M |
FACS, WB | done |
| human CCR4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR4 mAb |
in preparation |
| human CCR5 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR5 mAb |
in preparation |
| human CCR6 (CD196) | Character --> anti-mouse CCR6 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR6 mAb (C6Mab-19; mouse IgG1, kappa) | specific for human CCR6; expressed in HepG2 or HuH-7; peptide immunization |
FACS, IHC, ELISA | C6Mab-19 |
| human CCR7 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR7 mAb |
in preparation |
| human CCR8 | Character --> anti-mouse CCR8 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR8 mAb (C8Mab-20; mouse IgG1, kappa) |
specific for human CCR8; peptide immunization; Kd: 3.2 x 10^-7 M; ref: S19017D, L263G8 (BioLegend); 433H (BD) | FACS | done | ||
| anti-hCCR8 mAb (C8Mab-21; mouse IgM, kappa) | specific for human CCR8 CBIS method Kd: 6.5 x 10^-8 M |
FACS | C8Mab-21 | done |
| human CCR9 (CD199) | Character --> anti-mouse CCR9 | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR9 mAb (C9Mab-1; mouse IgG1, kappa) | specific for human CCR9; developmed by CBIS method; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS |
C9Mab-1;
epitope ICC |
done | BD; exbio |
| anti-hCCR9 mAb (C9Mab-6; mouse IgG1, kappa) | specific for human CCR9; established by CBIS method; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-8; mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-9; mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-10; mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-11; mouse IgG2a, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS, WB |
C9Mab-11 epitope |
done | |
| anti-hCCR9 mAb (C9Mab-12; mouse IgG1, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-13; mouse IgG2a, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-14; mouse IgG1, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-1016; mouse IgG1, kappa) |
specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-17; mouse IgG2b, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-18; mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-1019; mouse IgG1, kappa) |
specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done | ||
| anti-hCCR9 mAb (C9Mab-21; mouse IgG3, kappa) | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | done |
| human CCR10 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR10 mAb |
in preparation |
| human CCR11 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR11 mAb |
in preparation |
| human CXCR1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCXCR1 mAb |
in preparation |
| human CXCR2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCXCR2 mAb |
in preparation |
| human CXCR3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCXCR3 mAb |
in preparation |
| human CXCR4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCXCR4 mAb |
in preparation |
| human CXCR5 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCXCR5 mAb |
in preparation |
| human CXCR6 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCXCR6 mAb |
in preparation |
| human CXCR7 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCXCR7 mAb |
in preparation |
| human XCR1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hXCR1 mAb (X1Mab-4; mouse IgG1, kappa) | specific for human XCR1; established by peptide immunization | FACS | done | ||
| anti-hXCR1 mAb (X1Mab-29; mouse IgM, kappa) | specific for human XCR1; established by peptide immunization | FACS | done | ||
| anti-hXCR1 mAb (X1Mab-47; mouse IgM, kappa) | specific for human XCR1; established by CBIS (immunization of MDA-MB-157/PA-hXCR1) | FACS |
EGFR/HER2/HER3/HER4
| mouse EGFR domain-I | Character --> human EGFR | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EGFR mAb; EMab-300 (rat IgG1, kappa) | specific for mouse EGFR | FACS | EMab-300 | done | |
| anti-EGFR mAb; EMab-305 (rat IgG1, lambda) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-306 (rat IgG1, lambda) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-307 (rat IgG2a, kappa) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-308 (rat IgG2a, kappa) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-309 (rat IgG2a, kappa) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb (EMab-310; rat IgG1, kappa) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-311 (rat IgG1, kappa) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-312 (rat IgM, kappa) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-313 (rat IgG1, kappa) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-314 (rat IgG1, kappa) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-315 (rat IgG2a, kappa) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-316 (rat Ig2a, lambda) | specific for mouse EGFR; crossreacts with human EGFR | FACS | |||
| anti-EGFR mAb; EMab-317 (rat IgG1, kappa) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-318 (rat IgG1, lambda) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-319 (rat IgG1, kappa) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-320 (rat IgG1, kappa) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-321 (rat IgG1, kappa) | specific for mouse EGFR | FACS, WB(weak) | |||
| anti-EGFR mAb; EMab-322 (rat IgG1, kappa) | specific for mouse EGFR | FACS, WB(weak) | |||
| anti-EGFR mAb; EMab-323 (rat IgG2a, kappa) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-325 (rat IgG1, kappa) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-326 (rat Ig) | specific for mouse EGFR | FACS | |||
| anti-EGFR mAb; EMab-327 (rat Ig) | specific for mouse EGFR | FACS | |||
| mouse EGFR domain-I | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb; EMab-300-scFv-Fc (mouse IgG2a) | scFv of EMab-300 | FACS | done | ||
| mouse EGFR domain-II | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb; EMab-301 (rat IgM, kappa) | mouse EGFR was immunized using CBIS; cross-react with human EGFR | FACS, WB | done | ||
| mouse EGFR domain-II | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb; EMab-301-rG2a (rat IgG2a, kappa) | rat IgG2a version of EMab-301; mouse EGFR was immunized using CBIS; cross-react with human EGFR | FACS, WB | done | ||
| mouse EGFR domain-III | Character | Application | Ref | Gene cloning | Company |
| anti-mouse/human EGFR mAb; EMab-88 (mouse IgG1, kappa) | specific for EGFR; EMab-88 was developed against human EGFR; crossreacts with mouse EGFR (domain-III) | FACS | data | done | |
| human EGFR domain-I | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (EMab-23; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-I | FACS | done | ||
| anti-EGFR mAb (EMab-78; mouse IgG2b, kappa) |
specific for EGFR; reacts with domain-I | FACS | done | ||
| anti-EGFR mAb (EMab-129; mouse IgG1, lambda) |
specific for EGFR; reacts with domain-I | FACS | done | ||
| human EGFR domain-II | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (EMab-19; mouse IgG2a, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-II | FACS | done | ||
| anti-EGFR mAb (EMab-33; mouse IgG1, kappa) |
specific for EGFR; reacts with domain-II | FACS | done | ||
| anti-EGFR mAb (EMab-57; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-II | FACS | done | ||
| anti-EGFR mAb (EMab-76; mouse IgG1, kappa) |
specific for EGFR; reacts with domain-II | FACS | done | ||
| human EGFR domain-III | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (EMab-134; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC | EMab-134
epitope-1; -2 AirID |
done |
abcam BD wako |
| anti-EGFR mAb (134-mG2a; mouse IgG2a, kappa) |
mouse IgG2a version of EMab-134; specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC, ADCC/CDC, antitumor activities | 134-mG2a | done | |
| anti-EGFR mAb (EMab-51; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC | EMab-51 epitope |
done | |
| anti-EGFR mAb (51-mG2a; mouse IgG2a, kappa) |
mouse IgG2a version of EMab-51specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | done | ||
| anti-EGFR mAb (51-mG2a-f; mouse IgG2a, kappa) |
core fucose-deficient mouse IgG2a version of EMab-51; specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | done | ||
| anti-EGFR mAb (EMab-17; mouse IgG2a, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, ADCC/CDC, antitumor activities | EMab-17 metastasis |
done | |
| anti-EGFR mAb (recEMab-17-f; mouse IgG2a) |
core fucose-deficient mouse IgG2a version of EMab-17; specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, ADCC/CDC, antitumor activities | done | ||
| anti-EGFR mAb (EMab-1; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | done | ||
| anti-EGFR mAb (EMab-32; mouse IgG2a, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | done | ||
| anti-EGFR mAb (EMab-114; mouse IgG2b, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | done | ||
| anti-EGFR mAb (EMab-125; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB | done | ||
| anti-EGFR mAb (EMab-139; mouse IgG1, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB | done | ||
| anti-EGFR mAb (EMab-151; mouse IgG2b, kappa) |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | done | ||
| anti-EGFR mAb (cetuximab; human IgG1,kappa) |
specific for EGFR (Erbitax) | FACS | done | ||
| anti-EGFR mAb (panitumumab; human IgG2,kappa) |
specific for EGFR (Vectibix; epitope) | FACS | done | ||
| human EGFR domain-IV | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (EMab-95; mouse IgG1, kappa) |
specific for EGFR; reacts with domain-IV | FACS | done | ||
| anti-EGFR mAb (EMab-110; mouse IgG1, kappa) |
specific for EGFR; reacts with domain-IV | FACS | done | ||
| dog EGFR | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (134-mG2a-f; mouse IgG2a) |
core fucose-deficient mouse IgG2a version of EMab-134; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | CHO/dEGFR OS; Fibro Mammary |
done | |
| anti-EGFR mAb (E134Bf; canine IgGB, kappa) |
core fucose-deficient canine IgGB version of EMab-134; specific for EGFR | FACS, WB, IHC, ADCC, CDC, antitumor activities | Mammary Fibro & Osteo |
done | |
| bispecific | Character | Application | Ref | Gene cloning | Company |
| anti-dog EGFR-dog HER2 mAb (E134B-H77scFv-f) |
bispecific mAb for EGFR and HER2 | FACS, WB, IHC, ADCC, CDC, antitumor activities | E134B-H77scFv-f | done | |
| anti-EGFR-PDPN mAb (E134-NZ1scFv-mG2a-f) |
bispecific mAb for EGFR and PDPN | FACS, WB, IHC, ADCC, CDC, antitumor activities | done |
| mouse HER2 (CD340) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb (H2Mab-300 ; rat IgG2b, kappa) |
specific for mouse HER2 (domain-I)
does not cross-react with dog HER2 |
FACS | H2Mab-300 | done | |
| anti-HER2 mAb (H2Mab-303 ; rat IgG2a, kappa) |
specific for mouse HER2 (domain-I)
does not cross-react with dog HER2 |
FACS | done | ||
| anti-HER2 mAb (H2Mab-304 ; rat IgG1, kappa) |
specific for mouse HER2 (domain-I)
does not cross-react with dog HER2 |
FACS, WB | H2Mab-304 | done | |
| anti-HER2 mAb (H2Mab-307 ; rat IgG2a, kappa) |
specific for mouse HER2 (domain-I)
does not cross-react with dog HER2 |
FACS | done | ||
| anti-HER2 mAb (H2Mab-314 ; rat IgG1, kappa) |
specific for mouse HER2 (domain-I)
does not cross-react with dog HER2 |
FACS, WB | done | ||
| HER2 domain-I | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H2Mab-77; mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2; (ref: TNBC) | FACS, WB, IHC | H2Mab-77 | done | BioLegnd |
| anti-HER2 mAb (H2Mab-77-mG2a-f; mouse IgG2a) |
specific for HER2; crossreacts with dog HER2; (ref: TNBC) | FACS, WB, IHC | 77-mG2a-f | done | |
| anti-HER2 mAb (H2Mab-77-hG1; human IgG1) |
specific for HER2; crossreacts with dog HER2; (ref: TNBC) | FACS, WB, IHC | done | ||
| anti-HER2 mAb (H77Bf; canine IgGB, kappa) |
core fucose-deficient canine IgGB version of H2Mab-77 | FACS, WB, IHC, ADCC/CDC, antitumor activities | H77Bf OS fibro |
done | |
| anti-HER2 mAb (H2Mab-119; mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | H2Mab-119 structure H2Mab-250 |
done | |
| anti-HER2 mAb (H2Mab-119-mG2a-f; mouse IgG2a) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | 119-mG2a-f | done | |
| anti-HER2 mAb (H2Mab-119-hG1; human IgG1) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | done | ||
| anti-HER2 mAb (H2Mab-139; mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | H2Mab-139 | done | abcam |
| anti-HER2 mAb (H2Mab-139-mG2a;mouse IgG2a) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | done | ||
| anti-HER2 mAb (H2Mab-139-mG2a-f; mouse IgG2a) |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | 139-mG2a-f | done | |
| anti-HER2 mAb (H2Mab-1245; mouse IgG1,kappa) |
Mab-34; specific for human HER2 does not cross-react with endogenous dog HER2 |
FACS | done | ||
| anti-HER2 mAb (H2Mab-1268; mouse IgG1,kappa) |
Mab-35; specific for HER2 or endogenous dog HER2 | FACS | done | ||
| anti-HER2 mAb (H2Mab-1278; mouse IgG1,kappa) |
Mab-38; specific for HER2 or endogenous dog HER2 | FACS | done | ||
| HER2 domain-II | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H2Mab-32; mouse IgG1, kappa) |
specific for HER2 | FACS |
|
done | |
| anti-HER2 mAb (H2Mab-133; mouse IgG1, kappa) |
specific for HER2 | FACS |
|
done | |
| anti-HER2 mAb (H2Mab-193; mouse IgG1, kappa) |
specific for HER2 | FACS | H2Mab-250 | done | |
| anti-HER2 mAb (H2Mab-215; mouse IgG1, kappa) |
specific for HER2 | FACS | H2Mab-250 | done | |
| (anti-HER2 mAb (pertuzumab; human IgG1,kappa) |
specific for HER2 (Perjeta) | FACS | done | ||
| HER2 domain-III | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H2Mab-19; mouse IgG2b, kappa) |
specific for HER2; crossreacts with mouse HER2 (CHO/mHER2) or dog HER2; not react with NMuMG (mouse breast cancer) | FACS, ADCC/CDC, antitumor activities | PC; CRC; GBM | done | |
| anti-HER2 mAb (H2Mab-181; mouse IgG1, kappa) |
specific for HER2; crossreacts with dog HER2; domain-III; epitope: p373-392 | FACS, WB, IHC | H2Mab-181 epitope |
done | |
| anti-HER2 mAb (H2Mab-1180; mouse IgG1, kappa) |
Mab-33; specific for human HER2 does not cross-react with endogenous dog HER2 |
FACS | done | ||
| anti-HER2 mAb (H2Mab-1190; mouse IgG1,kappa) |
Mab-36; specific for HER2 does not cross-react with endogenous dog HER2 |
FACS | done | ||
| anti-HER2 mAb (H2Mab-1262; mouse IgG1,kappa) |
Mab-37; specific for HER2 does not cross-react with endogenous dog HER2 |
FACS | done | ||
| HER2 domain-IV | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H2Mab-41; mouse IgG2b, kappa) |
specific for HER2; crossreacts with dog HER2; domain-IV | FACS, antitumor activities | H2Mab-41
dogHER2 |
done | |
| (anti-HER2 mAb (trastuzumab; human IgG1,kappa) |
specific for HER2 | FACS | H2Mab-250 H2Mab-214 |
done | |
| anti-HER2 mAb (trastuzumab-f; human IgG1,kappa) |
defucosylated trastuzumab; specific for HER2 | FACS |
250_in vivo |
done | |
| anti-HER2 mAb (tras-mG2a-f; mouse IgG2a,kappa) |
specific for HER2 mouse IgG2a-version of trastuzumab defucosylated |
FACS | 250_in vivo | done |
| HER3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti HER3 mAb (H3Mab-17; mouse IgG2a, kappa) |
specific for HER3 | FACS, ADCC/CDC, antitumor activities | H3Mab-17 | done | exbio |
| anti-HER3 mAb (patritumab; human IgG2,kappa) |
specific for HER3 (Patritumab) | FACS | done |
| HER4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER4 mAb (H4Mab-12; mouse IgG2a, kappa) | Kd: 3.1 x 10^-10 M for T-47D ref: clone P6-1 (BD; CosmoBio: rat IgG2a; Kd: 2.8 x 10^-10 M for T-47D) |
FACS | done | ||
| anti-HER4 mAb (H4Mab-16; mouse IgG1, kappa) | immunization of LN229/HER4 Kd: 1.2 x 10^-9 M for T-47D |
FACS | done |
Immune checkpoint
| KLRG1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-KLRG1 mAb (KLMab-1; mouse IgG1, kappa) |
specific for human KLRG1 | FACS, ICC | KLMab-1 ICC |
done |
| PD-L1 (CD274/B7H1) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PD-L1 mAb (L1Mab-13; mouse IgG1, kappa) |
specific for human PD-L1 | FACS, WB, IHC (cell), IHC (tissue), ELISA | L1Mab-13 | done | |
| anti-PD-L1 mAb (13-mG2a-f; mouse IgG2a, kappa) |
specific for human PD-L1; core fucose-deficient IgG2a of L1Mab-13 | FACS, WB, IHC (cell), IHC (tissue), ELISA, ADCC/CDC, antitumor activities | 13-mG2a-f | done | |
| dog PD-L1 | Character | Application | Ref | Gene cloning | Company |
| anti-dog PD-L1 mAb (L1Mab-347; mouse IgG1, kappa) |
specific for dog PD-L1 (extracellular domain) | FACS, IHC | done | ||
| anti-dog PD-L1 mAb (L1Mab-352; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | L1Mab-352 | done | |
| anti-dog PD-L1 mAb (L1Mab-354; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | L1Mab-354 | done |
| PD-L2 (CD273/B7H2) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PD-L2 mAb (L2Mab-1; mouse IgG2b, kappa) |
specific for human PD-L2 | FACS, WB, IHC (cell) | done |
| TIGIT | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-TIGIT mAb (TgMab-1; mouse IgG1, kappa) |
specific for human TIGIT | FACS KD: 6.7 x 10^-10 |
done | ||
| anti-TIGIT mAb (TgMab-2; mouse IgG1, kappa) |
specific for human TIGIT | FACS, WB, ICC KD: 3.5 x 10^-9 |
TgMab-2 ICC |
done | BD |
Monoclonal antibodies for the other membrane proteins
| CA4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CA4 mAb (CA4Mab-1; rat IgG1, kappa) |
specific for mouse carbonic anhydrase IV (CA4) | FACS, ELISA | done | ||
| anti-CA4 mAb (CA4Mab-2; rat IgG1, kappa) |
specific for mouse carbonic anhydrase IV (CA4) | FACS, ELISA | done |
| CD10 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD10 mAb (C10Mab-31; mouse IgG1, kappa) |
specific for CD10; CBIS method | FACS | C10Mab-31 RCC |
done |
| CD19 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD19 mAb (C19Mab-1; mouse IgG1, kappa) |
specific for CD19; CBIS method; LN229/CD19 immunization | FACS | C19Mab-1 | done | |
| anti-CD19 mAb (C19Mab-3; mouse IgG1, kappa) |
specific for CD19; CBIS method; ectodomain of CD19 immunization | IHC,WB | C19Mab-3 | done |
| CD20 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD20 mAb (C20Mab-11; mouse IgM, kappa) |
specific for CD20 | FACS, WB, IHC |
C20Mab-11 epitope |
ongoing | |
| anti-CD20 mAb (C20Mab-60; mouse IgG2a, kappa) |
specific for CD20; ref: rituximab | FACS, WB, IHC | C20Mab-60 epitope-1 epitope-2 |
done | BioLegnd |
| CD20 | Character | Application | Ref | Gene cloning | Company |
| anti-CD20 mAb (rituximab; human IgG1, kappa) |
specific for human CD20 (Rituxan) | FACS | done | ||
| anti-CD20 mAb (obinutuzumab; human IgG1, kappa) |
specific for human CD20 (GAZYVA) | FACS | done | ||
| anti-CD20 mAb (ofatumumab; human IgG1, kappa) |
specific for human CD20 (Kesimpta) | FACS | done |
| CD39 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD39 mAb (C39Mab-1; rat IgG2a, kappa) |
specific for mouse CD39 | FACS, WB |
C39Mab-1
epitope |
done | |
| anti-CD39 mAb (C39Mab-2; rat IgG2a, lambda) |
specific for mouse CD39 | FACS | C39Mab-2 | done | |
| CD39 | Character | Application | Ref | Gene cloning | Company |
| anti-CD39 mAb (C39Mab-1-ratM; rat IgM, kappa) |
specific for mouse CD39 | FACS, WB | done |
| CD44s | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44s mAb (C44Mab-5; mouse IgG1, kappa) |
Specific for CD44s (CD44 standard) | IHC, FACS, WB | C44Mab-5 epitope 5-mG2a-f |
done | abcam BioLegnd |
| anti-CD44s mAb (C44Mab-46; mouse IgG1, kappa) |
specific for CD44s (CD44 standard) | FACS, IHC, WB | C44Mab-46 epitope1 epitope2 C44Mab-46-mG2a |
done | |
| CD44v3 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v3 mAb (C44Mab-6; mouse IgG1, kappa) |
specific for CD44v3 (oral cancer and colon cancer) |
FACS, WB, IHC, ELISA | C44Mab-6(IJMS) FACS(CAS) |
done | |
| CD44v4 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v4 mAb (C44Mab-108; mouse IgG1, kappa) |
specific for CD44v4 (oral cancer) |
WB, IHC, ELISA | C44Mab-108(CIMB) epitope(MAB) |
done | Merck |
| CD44v5 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v5 mAb (C44Mab-3; mouse IgG1, kappa) |
specific for CD44v5 (pancreatic cancer) |
FACS, WB, IHC, ELISA | C44Mab-3 (antibodies) |
done | Merck |
| CD44v6 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v6 mAb (C44Mab-9; mouse IgG1, kappa) |
specific for CD44v6 (colon cancer) |
FACS, WB, IHC, ELISA | C44Mab-9 (IJMS) |
done | Merck |
| CD44v7 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v7/v8 mAb (C44Mab-34; mouse IgG1, kappa) |
specific for CD44v7/v8 (oral cancer) |
FACS, WB, IHC, ELISA | C44Mab-34 (Biomedicines) |
done | |
| CD44v8 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v8 mAb (C44Mab-94; mouse IgG1, kappa) |
specific for CD44v8 (gastric cancer) |
FACS, WB, IHC, ELISA | C44Mab-94 (antibodies) |
done | |
| CD44v9 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v9 mAb (C44Mab-1; mouse IgG1, kappa) |
specific for CD44v9 (colon cancer) |
FACS, WB, IHC, ELISA | C44Mab-1(CIMB) FACS(CAS) |
done | |
| CD44v10 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v10 mAb (C44Mab-18; mouse IgM, kappa) |
specific for CD44v10 (oral cancer) |
FACS, WB, IHC, ELISA | C44Mab-18(CIMB) C44Mab-18-mG2a |
done | |
| CD44s | Character | Application | Ref | Gene cloning | Company |
| anti-CD44s mAb (5-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-5; specific for CD44s (CD44 standard) | IHC, FACS, ADCC, CDC, antitumor activities | 5-mG2a-f | done | |
| anti-CD44s mAb (C44Mab-46-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-46 specific for CD44s (CD44 standard) |
IHC, FACS, WB | C44Mab-46-mG2a | done | |
| CD44v3 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v3 mAb (C44Mab-6-mG2a-f; mouse IgG2a) |
IgG2a version of C44Mab-6 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| CD44v4 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v4 mAb (C44Mab-112; mouse IgG1, kappa) |
specific for CD44v4 crossreact with mouse CD44 |
WB, IHC, ELISA | done | ||
| anti-CD44v4 mAb (C44Mab-118; mouse IgG1, kappa) |
specific for CD44v4 crossreact with mouse CD44 |
WB, IHC, ELISA | done | ||
| CD44v5 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v5 mAb (C44Mab-3-mG2a-f; mouse IgG2a) |
IgG2a version of C44Mab-3 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| CD44v6 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v6 mAb (C44Mab-9-mG2a-f; mouse IgG2a) |
IgG2a version of C44Mab-9 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| anti-CD44v6 mAb (bivatuzumab; human IgG1, kappa) |
specific for CD44v6 | ref | done | ||
| anti-CD44v6 mAb (biva-mG1; mouse IgG2a, kappa) |
specific for CD44v6 mouse IgG1 type |
||||
| CD44v7 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v7/v8 mAb (C44Mab-34-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-34 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| CD44v8 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v8 mAb (C44Mab-94-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-94 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| CD44v9 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v9 mAb (C44Mab-1-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-1 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| CD44v10 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v10 mAb (C44Mab-18-mG1; mouse IgG1, kappa) |
mouse IgG1 version of CD44v10 | FACS, WB, IHC, ELISA | done | ||
| anti-CD44v10 mAb (C44Mab-18-mG2a-f; mouse IgG2a) |
mouse IgG2a version of C44Mab-18 | FACS, WB, IHC, ELISA | C44Mab-18-mG2a | done |
| CD73 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD73 mAb (C73Mab-1; rat IgG2a, lambda) | specific for mouse CD73 | FACS | in preparation (Kaneko et al) |
||
| anti-CD73 mAb (C73Mab-2; rat IgG2a, lambda) | specific for mouse CD73 | FACS | |||
| anti-CD73 mAb (C73Mab-3; rat IgM) | specific for mouse CD73 | FACS | |||
| anti-CD73 mAb (C73Mab-4; rat IgG2a, lambda) | specific for mouse CD73 | FACS | |||
| anti-CD73 mAb (C73Mab-5; rat Ig) | specific for mouse CD73 | FACS | |||
| anti-CD73 mAb (C73Mab-6; rat IgG2a, kappa) | specific for mouse CD73 Kd: 1.4 x 10^-8 for CHO/mCD73 |
FACS, WB | ongoing | ||
| anti-CD73 mAb (C73Mab-7; rat Ig) | specific for mouse CD73 | FACS | |||
| anti-CD73 mAb (C73Mab-8; rat IgG2a, lambda) | specific for mouse CD73 Kd: 7.8 x 10^-9 for CHO/mCD73 |
FACS, WB | ongoing | ||
| anti-CD73 mAb (C73Mab-9; rat IgG2a, lambda) | specific for mouse CD73 Kd: 7.64 x 10^-9 for CHO/mCD73 |
FACS, WB | ongoing | ||
| anti-CD73 mAb (C73Mab-10; rat IgG2a, lambda) | specific for mouse CD73 | FACS | |||
| anti-CD73 mAb (C73Mab-11; rat Ig) | specific for mouse CD73 | FACS | |||
| anti-CD73 mAb (C73Mab-12; rat Ig) | specific for mouse CD73 | FACS | |||
| anti-CD73 mAb (C73Mab-13; rat IgG2b, lambda) | specific for mouse CD73 | FACS | |||
| anti-CD73 mAb (C73Mab-14; rat Ig) | specific for mouse CD73 | FACS | |||
| anti-CD73 mAb (C73Mab-15; rat IgG2a, lambda) | specific for mouse CD73 | FACS | |||
| anti-CD73 mAb (C73Mab-16; rat IgG2a, lambda) | specific for mouse CD73 Kd: 5.78 x 10^-9 for CHO/mCD73 |
FACS, WB | ongoing | ||
| anti-CD73 mAb (C73Mab-17; rat IgG2a, lambda) | specific for mouse CD73 | FACS |
| CD133 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD133 mAb (CMab-43; mouse IgG2a, kappa) |
specific for CD133 | FACS, WB, IHC, ADCC/CDC, antitumor activities |
CMab-43 in vivo |
done |
abcam BD |
| anti-CD133 mAb (CMab-44; mouse IgG1, kappa) |
specific for CD133; detects AML |
FACS, WB | done |
| CD271 (NGFR) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD271 mAb (G4B1; mouse IgG2a, kappa) |
cancer-specific mAb for CD271 | FACS, WB, IHC | anti-CD271 mAb | done | Merck |
| CD273 (PD-L2/B7H2) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PD-L2 mAb | --> PD-L2 |
| CD274 (PD-L1/B7H1) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PD-L1 mAb | --> PD-L1 |
| CD276 (B7H3) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD276 mAb (C276Mab-1; mouse IgG1, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-2; mouse IgG2b, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-3; mouse IgG1, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-4; mouse IgG1, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-5; mouse IgG1, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-6; mouse IgG1, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-7; mouse IgG3, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-8; mouse IgG2a, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-9; mouse IgM, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-10; mouse IgM, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-11; mouse IgG2a, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-12; mouse IgG2a, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-13; mouse IgG2a, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-14; mouse IgG2b, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-15; mouse IgG2a, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-16; mouse IgG2a, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-17; mouse IgG1, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-18; mouse IgG2a, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-19; mouse IgG1, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-20; mouse IgG2a, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-21; mouse IgG1, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-22; mouse IgG1, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-23; mouse IgG2b, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-24; mouse IgG2b, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-25; mouse IgG1, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-26; mouse IgG1, kappa) | specific for CD276 | FACS, WB | |||
| anti-CD276 mAb (C276Mab-27; mouse IgG1, kappa) | specific for CD276 | ||||
| anti-CD276 mAb (C276Mab-28; mouse IgG1, kappa) | specific for CD276 |
| CDH1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH1 mAb Ca1Mab series |
specific for CDH1 |
| CDH2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH2 mAb Ca2Mab series |
specific for CDH2 |
| CDH3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH3 mAb Ca3Mab-5 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
| anti-CDH3 mAb Ca3Mab-6 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
| anti-CDH3 mAb Ca3Mab-7 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
| anti-CDH3 mAb Ca3Mab-8 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
| anti-CDH3 mAb Ca3Mab-12 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
| anti-CDH3 mAb Ca3Mab-16 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
| anti-CDH3 mAb Ca3Mab-17 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
| anti-CDH3 mAb Ca3Mab-18 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
| anti-CDH3 mAb Ca3Mab-19 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB | |||
| anti-CDH3 mAb Ca3Mab-20 (mouse IgG1, kappa) |
specific for CDH3 | FACS, WB |
| CDH4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH4 mAb Ca4Mab series |
specific for CDH4 |
| CDH5 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH5 mAb Ca5Mab series |
specific for CDH5 |
| CDH6 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH6 mAb Ca6Mab series |
specific for CDH6 |
| CDH7 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH7 mAb Ca7Mab series |
specific for CDH7 |
| CDH8 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH8 mAb (Ca8Mab-1, mouse IgG1, kappa) |
specific for CDH8 Kd: 1.3x10^-8 M |
FACS, WB(weak), IHC | |||
| anti-CDH8 mAb (Ca8Mab-2, mouse IgG1, kappa) |
specific for CDH8 Kd: 1.4x10^-7 M |
FACS, WB(weak) | |||
| anti-CDH8 mAb (Ca8Mab-3, mouse IgG1, kappa) |
specific for CDH8 | FACS | |||
| anti-CDH8 mAb (Ca8Mab-4, mouse IgG1, kappa) |
specific for CDH8 Kd: 3.8x10^-9 M |
FACS, WB, IHC | in preparation (Nakamura et al) |
| CDH9 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH9 mAb Ca9Mab series |
specific for CDH9 |
| CDH10 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH10 mAb Ca10Mab series |
specific for CDH10 |
| CDH11 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH11 mAb Ca11Mab series |
specific for CDH11 |
| CDH12 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH12 mAb Ca12Mab-1 (mouse IgG1, kappa) |
specific for CDH12 | FACS | in preparation (Li et al) | ||
| anti-CDH12 mAb Ca12Mab-2 (mouse IgG1, kappa) |
specific for CDH12 | FACS | |||
| anti-CDH12 mAb Ca12Mab-3 (mouse IgG1, kappa) |
specific for CDH12 | FACS | |||
| anti-CDH12 mAb Ca12Mab-4 (mouse IgG1, kappa) |
specific for CDH12 | FACS | |||
| anti-CDH12 mAb Ca12Mab-5 (mouse IgG1, kappa) |
specific for CDH12 | FACS | |||
| anti-CDH12 mAb Ca12Mab-6 (mouse IgG1, kappa) |
specific for CDH12 | FACS | |||
| anti-CDH12 mAb Ca12Mab-7 (mouse IgG1, kappa) |
specific for CDH12 | FACS | |||
| anti-CDH12 mAb Ca12Mab-8 (mouse Ig) |
specific for CDH12 | FACS | |||
| anti-CDH12 mAb Ca12Mab-9 (mouse Ig) |
specific for CDH12 | FACS | |||
| anti-CDH12 mAb Ca12Mab-10 (mouse Ig) |
specific for CDH12 | FACS | |||
| anti-CDH12 mAb Ca12Mab-11 (mouse Ig) |
specific for CDH12 | FACS |
| CDH13 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH13 mAb Ca13Mab-1 (mouse Ig) |
specific for CDH13 no p.c. mAbs |
FACS | Kobayashi et al | ||
| anti-CDH13 mAb Ca13Mab-2 (mouse Ig) |
specific for CDH13 | FACS | |||
| anti-CDH13 mAb Ca13Mab-3 (mouse Ig) |
specific for CDH13 | FACS | |||
| anti-CDH13 mAb Ca13Mab-4 (mouse Ig) |
specific for CDH13 | FACS | |||
| anti-CDH13 mAb Ca13Mab-5 (mouse Ig) |
specific for CDH13 | FACS |
| CDH15 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH15 mAb Ca15Mab-1 (mouse IgG1, kappa) |
specific for CDH15 | FACS (Saos-2, C2C12), WB, IHC | Ubukata et al | ||
| anti-CDH15 mAb Ca15Mab-2 (mouse IgG1, kappa) |
specific for CDH15 | FACS, WB, IHC | |||
| anti-CDH15 mAb Ca15Mab-3 (mouse IgG1, kappa) |
specific for CDH15 | FACS, WB, IHC | |||
| anti-CDH15 mAb Ca15Mab-4 (mouse IgG1, kappa) |
specific for CDH15 | FACS, WB, IHC | |||
| anti-CDH15 mAb Ca15Mab-5 (mouse IgG1, kappa) |
specific for CDH15 | FACS, WB, IHC | |||
| anti-CDH15 mAb Ca15Mab-6 (mouse IgG1, kappa) |
specific for CDH15 | FACS, WB | |||
| anti-CDH15 mAb Ca15Mab-7 (mouse IgG1, kappa) |
specific for CDH15 | FACS | |||
| anti-CDH15 mAb Ca15Mab-8 (mouse IgG1, kappa) |
specific for CDH15 | FACS, WB, IHC |
| CDH16 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH16 mAb Ca16Mab series |
specific for CDH16 |
| CDH17 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH17 mAb Ca17Mab series |
specific for CDH17 |
| CDH18 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH18 mAb Ca18Mab series |
specific for CDH18 |
| CDH19 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH19 mAb Ca19Mab series |
specific for CDH19 |
| CDH20 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH20 mAb Ca20Mab series |
specific for CDH20 |
| CDH21 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH21 mAb Ca21Mab series |
specific for CDH21 |
| CDH22 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH22 mAb Ca22Mab series |
specific for CDH22 |
| CDH23 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH23 mAb Ca23Mab series |
specific for CDH23 |
| CDH24 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH24 mAb Ca24Mab series |
specific for CDH24 |
| CDH25 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CDH25 mAb Ca25Mab series |
specific for CDH25 |
| mouse EpCAM (CD326) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EpCAM mAb (EpMab-160; rat IgG2b, kappa) |
specific for mouse EpCAM | FACS | in preparation (Li G et al) | ||
| anti-EpCAM mAb (EpMab-161; rat IgG2b, kappa) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-162; rat IgG2a, kappa) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-163; rat IgG2c, kappa) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-164; rat IgM, kappa) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-165; rat IgG2a, kappa) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-166; rat IgM, kappa) |
specific for mouse EpCAM crossreact with human EpCAM (only exogenous) |
FACS | |||
| anti-EpCAM mAb (EpMab-167; rat IgM, kappa) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-168; rat Ig) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-169; rat Ig) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-170; rat Ig) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-171; rat Ig) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-172; rat Ig) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-173; rat Ig) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-174; rat Ig) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-175; rat Ig) |
specific for mouse EpCAM crossreact with human EpCAM (only exogenous) |
FACS | |||
| anti-EpCAM mAb (EpMab-176; rat Ig) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-177; rat Ig) |
specific for mouse EpCAM | FACS | |||
| anti-EpCAM mAb (EpMab-178; rat Ig) |
specific for mouse EpCAM | FACS | |||
| human EpCAM (CD326) | Character | Application | Ref | Gene cloning | Company |
| anti-EpCAM mAb (EpMab-16; mouse IgG2a, kappa) |
specific for EpCAM | FACS, WB, IHC | EpMab-16 (1)
EpMab-16 (2) |
done | merck |
| anti-EpCAM mAb (EpMab-37; mouse IgG1, kappa) |
specific for EpCAM | FACS, WB, IHC | EpMab-37 epitope |
done | |
| anti-EpCAM mAb (EpMab-37-mG2a-f; mouse IgG2a) |
specific for EpCAM | FACS, WB, IHC, ADCC, CDC, antitumor activities |
EpMab-37 (1) EpMab-37 (2) |
done | |
| anti-EpCAM mAb (EpMab-3; mouse IgG1, kappa) |
specific for EpCAM | FACS | done |
| EphA1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA1 mAb Ea1Mab-5 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB | |||
| anti-EphA1 mAb Ea1Mab-7 (mouse IgG2a, kappa) |
specific for EphA1 | FACS, WB | |||
| anti-EphA1 mAb Ea1Mab-14 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB | |||
| anti-EphA1 mAb Ea1Mab-15 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB | |||
| anti-EphA1 mAb Ea1Mab-20 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB | |||
| anti-EphA1 mAb Ea1Mab-28 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB | |||
| anti-EphA1 mAb Ea1Mab-30 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB | |||
| anti-EphA1 mAb Ea1Mab-35 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB | |||
| anti-EphA1 mAb Ea1Mab-43 (mouse IgG2a, kappa) |
specific for EphA1 | FACS, WB | |||
| anti-EphA1 mAb Ea1Mab-46 (mouse IgG1, kappa) |
specific for EphA1 | FACS, WB |
| EphA2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA2 mAb Ea2Mab-1 (mouse IgG1, kappa) |
specific for EphA2 ref: clone SHM16 (BioLegend; Kd: 8.4 x 10^-9 for CHO/hEphA2) |
FACS | |||
| anti-EphA2 mAb Ea2Mab-2 (mouse IgG2a, kappa) |
specific for EphA2 | FACS | |||
| anti-EphA2 mAb Ea2Mab-3 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
| anti-EphA2 mAb Ea2Mab-4 (mouse IgG2b, kappa) |
specific for EphA2 | FACS | |||
| anti-EphA2 mAb Ea2Mab-5 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
| anti-EphA2 mAb Ea2Mab-6 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
| anti-EphA2 mAb Ea2Mab-7 (mouse IgG1, kappa) |
specific for EphA2 Kd: 7.7 x 10^-9 for CHO/hEphA2 |
FACS, WB, IHC | Ea2Mab-7 | done | |
| anti-EphA2 mAb Ea2Mab-8 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
| anti-EphA2 mAb Ea2Mab-9 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
| anti-EphA2 mAb Ea2Mab-10 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
| anti-EphA2 mAb Ea2Mab-11 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
| anti-EphA2 mAb Ea2Mab-12 (mouse IgG1, kappa) |
specific for EphA2 | FACS | |||
| EphA2 | Character | Application | Ref | Gene cloning | Company |
| anti-EphA2 mAb Ea2Mab-7-mG2a (mouse IgG2a, kappa) |
mouse IgG2a version of Ea2Mab-7 | FACS, WB, IHC | |||
| anti-EphA2 mAb Ea2Mab-7-hG1 (human IgG1, kappa) |
human IgG1 version of Ea2Mab-7 | FACS, WB, IHC |
| EphA3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA3 mAb Ea3Mab-1 (mouse IgG1, kappa) |
specific for EphA3; Kd: 4.8 x 10^-10; ref: clone: IIIA4 (absolute antibody; Kd: 6.3 x 10^-10) | FACS, IHC | in preparation | ||
| anti-EphA3 mAb Ea3Mab-2 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
| anti-EphA3 mAb Ea3Mab-3 (mouse IgG1, kappa) |
specific for EphA3; Kd: 8.8 x 10^-9 | FACS, IHC | |||
| anti-EphA3 mAb Ea3Mab-4 (mouse IgG1, kappa) |
specific for EphA3; Kd: 2.3 x 10^-9 | FACS | |||
| anti-EphA3 mAb Ea3Mab-5 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
| anti-EphA3 mAb Ea3Mab-6 (mouse IgM, kappa) |
specific for EphA3 | FACS | |||
| anti-EphA3 mAb Ea3Mab-7 (mouse IgG1, kappa) |
specific for EphA3; Kd: 6.7 x 10^-9 | FACS | |||
| anti-EphA3 mAb Ea3Mab-8 (mouse IgG1, kappa) |
specific for EphA3; Kd: 4.6 x 10^-9 | FACS, IHC | |||
| anti-EphA3 mAb Ea3Mab-9 (mouse IgG1, kappa) |
specific for EphA3 | FACS, IHC | |||
| anti-EphA3 mAb Ea3Mab-10 (mouse IgG1, kappa) |
specific for EphA3; Kd: 2.5 x 10^-9 | FACS, IHC | in preparation | ||
| anti-EphA3 mAb Ea3Mab-11 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
| anti-EphA3 mAb Ea3Mab-12 (mouse IgG1, kappa) |
specific for EphA3; Kd: 4.6 x 10^-9 | FACS, IHC | |||
| anti-EphA3 mAb Ea3Mab-13 (mouse IgG1, kappa) |
specific for EphA3 | FACS, IHC | |||
| anti-EphA3 mAb Ea3Mab-14 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
| anti-EphA3 mAb Ea3Mab-15 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
| anti-EphA3 mAb Ea3Mab-16 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
| anti-EphA3 mAb Ea3Mab-17 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
| anti-EphA3 mAb Ea3Mab-18 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
| anti-EphA3 mAb Ea3Mab-19 (mouse IgG1, kappa) |
specific for EphA3 | FACS | |||
| anti-EphA3 mAb Ea3Mab-20 (mouse IgG1, kappa) |
specific for EphA3 | FACS |
| EphA4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA4 mAb Ea4Mab-1 (mouse IgG1, kappa) |
specific for EphA4 | FACS | |||
| anti-EphA4 mAb Ea4Mab-2 (mouse IgG1, kappa) |
specific for EphA4 | FACS, IHC | |||
| anti-EphA4 mAb Ea4Mab-3 (mouse IgG1, kappa) |
specific for EphA4 | FACS, WB, IHC | in preparation (Li et al) |
ongoing | |
| anti-EphA4 mAb Ea4Mab-4 (mouse IgG2b, kappa) |
specific for EphA4 | FACS | |||
| anti-EphA4 mAb Ea4Mab-5 (mouse IgG1, kappa) |
specific for EphA4 | FACS, IHC | |||
| anti-EphA4 mAb Ea4Mab-6 (mouse IgG1, kappa) |
specific for EphA4 | FACS, IHC | |||
| anti-EphA4 mAb Ea4Mab-7 (mouse IgG1, kappa) |
specific for EphA4 | FACS | |||
| anti-EphA4 mAb Ea4Mab-8 (mouse IgG1, kappa) |
specific for EphA4 | FACS | |||
| anti-EphA4 mAb Ea4Mab-9 (mouse IgG1, kappa) |
specific for EphA4 | FACS | |||
| anti-EphA4 mAb Ea4Mab-10 (mouse IgG1, kappa) |
specific for EphA4 | FACS | |||
| anti-EphA4 mAb Ea4Mab-11 (mouse IgG1, kappa) |
specific for EphA4 | FACS | |||
| anti-EphA4 mAb Ea4Mab-12 (mouse IgG1, kappa) |
specific for EphA4 | FACS | |||
| anti-EphA4 mAb Ea4Mab-13 (mouse IgG1, kappa) |
specific for EphA4 | FACS |
| EphA5 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA5 mAb Ea5Mab-1 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method; p.c. (clone 86731 (R&D); Kd: 3.9 x 10^-8) |
FACS, IHC | |||
| anti-EphA5 mAb Ea5Mab-2 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS | |||
| anti-EphA5 mAb Ea5Mab-3 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS, IHC | |||
| anti-EphA5 mAb Ea5Mab-4 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS | |||
| anti-EphA5 mAb Ea5Mab-5 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method (Kd: 3.0 x 10^-8) |
FACS, WB, IHC | in preparation (Li et al) |
ongoing | |
| anti-EphA5 mAb Ea5Mab-6 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS | |||
| anti-EphA5 mAb Ea5Mab-7 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method (Kd: 3.2 x 10^-9) |
FACS, WB, IHC | in preparation (Li et al) |
ongoing | |
| anti-EphA5 mAb Ea5Mab-8 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS | |||
| anti-EphA5 mAb Ea5Mab-9 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS | |||
| anti-EphA5 mAb Ea5Mab-10 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS | |||
| anti-EphA5 mAb Ea5Mab-11 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS | |||
| anti-EphA5 mAb Ea5Mab-12 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS | |||
| anti-EphA5 mAb Ea5Mab-13 (mouse IgG1, kappa) |
specific for human EphA5 established by CBIS method |
FACS |
| EphA6 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA6 mAb (Ea6Mab-1, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method no ref mAb |
FACS | in preparation (Li G et al) |
||
| anti-EphA6 mAb (Ea6Mab-2, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method |
FACS | |||
| anti-EphA6 mAb (Ea6Mab-3, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method |
FACS | |||
| anti-EphA6 mAb (Ea6Mab-4, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method |
FACS | |||
| anti-EphA6 mAb (Ea6Mab-5, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method |
FACS | |||
| anti-EphA6 mAb (Ea6Mab-6, mouse IgM, kappa) |
specific for human EphA6 established by CBIS method |
FACS | |||
| anti-EphA6 mAb (Ea6Mab-7, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method |
FACS | |||
| anti-EphA6 mAb (Ea6Mab-8, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method |
FACS | |||
| anti-EphA6 mAb (Ea6Mab-9, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method |
FACS | |||
| anti-EphA6 mAb (Ea6Mab-10, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method |
FACS | |||
| anti-EphA6 mAb (Ea6Mab-11, mouse IgG1, kappa) |
specific for human EphA6 established by CBIS method |
FACS | |||
| anti-EphA6 mAb (Ea6Mab-12, mouse Ig) |
specific for human EphA6 established by CBIS method |
FACS |
| EphA7 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA7 mAb Ea7Mab-1 (mouse IgM, kappa) |
specific for human EphA7 | FACS | |||
| anti-EphA7 mAb Ea7Mab-2 (mouse IgG1, kappa) |
specific for human EphA7 Kd: 2.0 x 10^-9 M for CHO/EphA7 9.2 x 10^-9 M for LN229/EphA7 |
FACS, WB | |||
| anti-EphA7 mAb Ea7Mab-3 (mouse IgG1, kappa) |
specific for human EphA7 | FACS | |||
| anti-EphA7 mAb Ea7Mab-4 (mouse IgG1, kappa) |
specific for human EphA7 Kd: 1.7 x 10^-8 M for CHO/EphA7 2.7 x 10^-8 M for LN229/EphA7 |
FACS, WB | |||
| anti-EphA7 mAb Ea7Mab-5 (mouse IgG1, kappa) |
specific for human EphA7 | FACS, WB | in preparation | ongoing | |
| anti-EphA7 mAb Ea7Mab-6 (mouse IgG1, kappa) |
specific for human EphA7 | FACS | |||
| anti-EphA7 mAb Ea7Mab-7 (mouse IgG1, kappa) |
specific for human EphA7 | FACS | |||
| anti-EphA7 mAb Ea7Mab-8 (mouse IgG1, kappa) |
specific for human EphA7 Kd: 8.7 x 10^-9 M for CHO/EphA7 4.7 x 10^-8 M for LN229/EphA7 |
FACS, WB | |||
| anti-EphA7 mAb Ea7Mab-9 (mouse IgG1, kappa) |
specific for human EphA7 Kd: 6.5 x 10^-7 M for CHO/EphA7 6.7 x 10^-5 M for LN229/EphA7 |
FACS, WB | |||
| anti-EphA7 mAb Ea7Mab-10 (mouse IgG1, kappa) |
specific for human EphA7 Kd: 1.3 x 10^-7 M for CHO/EphA7 6.5 x 10^-8 M for LN229/EphA7 |
FACS, WB, IHC | ongoing | ||
| anti-EphA7 mAb Ea7Mab-11 (mouse IgM, kappa) |
specific for human EphA7 | FACS | |||
| anti-EphA7 mAb Ea7Mab-12 (mouse IgM, kappa) |
specific for human EphA7 | FACS | |||
| anti-EphA7 mAb Ea7Mab-13 (mouse IgG1, kappa) |
specific for human EphA7 | FACS, WB |
| EphA8 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA8 mAb (Ea8Mab-1, mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 1.9 x 10^-9 for CHO/EphA8; no ref mAb |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-2, mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 2.3 x 10^-9 for CHO/EphA8 |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-3, mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 3.4 x 10^-9 for CHO/EphA8 |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-4, mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 8.7 x 10^-9 for CHO/EphA8 |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-5, mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 2.2 x 10^-9 for CHO/EphA8 |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-6,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 5.5 x 10^-9 for CHO/EphA8 |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-7,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-8,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 4.1 x 10^-9 for CHO/EphA8 |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-9,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 1.3 x 10^-9 for CHO/EphA8 |
FACS | Ea8Mab-9 | ||
| anti-EphA8 mAb (Ea8Mab-10,mouse IgG1, lambda) |
specific for human EphA8 established by CBIS method |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-11,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method; Kd: 2.0 x 10^-9 |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-12,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-13,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-14,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-15,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-16,mouse IgG3, kappa) |
specific for human EphA8 established by CBIS method |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-17,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method |
FACS | |||
| anti-EphA8 mAb (Ea8Mab-18,mouse IgG1, kappa) |
specific for human EphA8 established by CBIS method |
FACS |
| EphA10 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphA10 mAb Ea10Mab-1 (mouse IgG1, kappa) |
specific for human EphA10 established by CBIS method |
FACS | in preparation (Ubukata et al) |
||
| anti-EphA10 mAb Ea10Mab-2 (mouse IgG1, kappa) |
specific for human EphA10 established by CBIS method |
FACS | |||
| anti-EphA10 mAb Ea10Mab-3 (mouse IgG1, kappa) |
specific for human EphA10 established by CBIS method |
FACS | |||
| anti-EphA10 mAb Ea10Mab-4 (mouse IgG1, kappa) |
specific for human EphA10 established by CBIS method |
FACS |
| EphB1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphB1 mAb Eb1Mab-1 (mouse IgG1, kappa) |
specific for human EphB1 Kd: 4.1 x 10^-9 M |
FACS | in preparation (Yamamoto et al) |
done | |
| anti-EphB1 mAb Eb1Mab-2 (mouse IgM, kappa) |
specific for human EphB1 | FACS | |||
| anti-EphB1 mAb Eb1Mab-3 (mouse IgG1, kappa) |
specific for human EphB1 Kd: 2.5 x 10^-9 M |
FACS |
| EphB2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphB2 mAb Eb2Mab-1 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 5.9 x 10^-9 for CHO/hEphB2; ref: clone 2H9 (BD; 3.4 x 10^-9 for CHO/hEphB2; Kd: 1.9 x 10^-9 for LS174T) | FACS (LS174T) | |||
| anti-EphB2 mAb Eb2Mab-2 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 6.4 x 10^-9 for CHO/hEphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-3 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 1.1 x 10^-9 for CHO/hEphB2; 3.6 x 10^-10 for LS174T | FACS | Eb2Mab-3 | done | |
| anti-EphB2 mAb Eb2Mab-4 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 3.3 x 10^-9 for CHO/hEphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-5 (mouse IgG3, kappa) |
specific for human EphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-6 (mouse IgM, kappa) |
specific for human EphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-7 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 5.2 x 10^-9 for CHO/hEphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-8 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 9.5 x 10^-9 for CHO/hEphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-9 (mouse IgM, kappa) |
specific for human EphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-10 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 3.4 x 10^-9 for CHO/hEphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-11 (mouse IgM, kappa) |
specific for human EphB2 | FACS | |||
| anti-EphB2 mAb Eb2Mab-12 (mouse IgG1, kappa) |
specific for human EphB2; Kd: 1.7 x 10^-9 for CHO/hEphB2; 4.4 x 10^-10 for LS174T | FACS | in preparation (Ubukata) | ||
| EphB2 | Character | Application | Ref | Gene cloning | Company |
| anti-EphB2 mAb Eb2Mab-3-mG2a-f (mouse IgG2a, kappa) |
mouse IgG2a version of Eb2Mab-3 | FACS | done | ||
| anti-EphB2 mAb Eb2Mab-12-mG2a-f (mouse IgG2a, kappa) |
mouse IgG2a version of Eb2Mab-12 | FACS | |||
| anti-EphB2 mAb Eb2Mab-12-hG1-f (human IgG1, kappa) |
human IgG1 version of Eb2Mab-12 | FACS |
| EphB3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphB3 mAb Eb3Mab-1 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method; ref: clone 647354 (R&D) |
FACS (LS174T) | in preparation (Li et al) |
||
| anti-EphB3 mAb Eb3Mab-2 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS | |||
| anti-EphB3 mAb Eb3Mab-3 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS | |||
| anti-EphB3 mAb Eb3Mab-4 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS | |||
| anti-EphB3 mAb Eb3Mab-5 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS, WB | |||
| anti-EphB3 mAb Eb3Mab-6 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS | |||
| anti-EphB3 mAb Eb3Mab-7 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS | |||
| anti-EphB3 mAb Eb3Mab-9 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS | |||
| anti-EphB3 mAb Eb3Mab-10 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS | |||
| anti-EphB3 mAb Eb3Mab-11 (mouse IgG1, kappa) |
specific for human EphB3 by CBIS method |
FACS | |||
| anti-EphB3 mAb Eb3Mab-12 (mouse Ig) |
specific for human EphB3 by CBIS method |
FACS | |||
| anti-EphB3 mAb Eb3Mab-13 (mouse Ig) |
specific for human EphB3 by CBIS method |
FACS | |||
| anti-EphB3 mAb Eb3Mab-14 (mouse Ig) |
specific for human EphB3 by CBIS method |
FACS | |||
| anti-EphB3 mAb Eb3Mab-15 (mouse Ig) |
specific for human EphB3 by CBIS method |
FACS | |||
| anti-EphB3 mAb Eb3Mab-16 (mouse Ig) |
specific for human EphB3 by CBIS method |
FACS | |||
| anti-EphB3 mAb Eb3Mab-17 (mouse Ig) |
specific for human EphB3 by CBIS method |
FACS | |||
| anti-EphB3 mAb Eb3Mab-18 (mouse Ig) |
specific for human EphB3 by CBIS method |
FACS |
| EphB4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphB4 mAb (Eb4Mab-1, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method ref: clone ab279601 (abcam) |
FACS, WB | |||
| anti-EphB4 mAb (Eb4Mab-2, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS | |||
| anti-EphB4 mAb (Eb4Mab-3, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS, WB | |||
| anti-EphB4 mAb (Eb4Mab-4, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS, WB | |||
| anti-EphB4 mAb (Eb4Mab-5, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS, WB | |||
| anti-EphB4 mAb (B4Mab-7, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS, WB, IHC | B4Mab-7 | done | |
| anti-EphB4 mAb (Eb4Mab-8, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS, WB | |||
| anti-EphB4 mAb (Eb4Mab-9, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS, WB, IHC | |||
| anti-EphB4 mAb (Eb4Mab-10, mouse IgG1, kappa) | specific for human EphB4 established by CBIS method |
FACS | |||
| EphB4 | Character | Application | Ref | Gene cloning | Company |
| anti-EphB4 mAb (Eb4Mab-7-mG2a-f, mouse IgG2a, kappa) | mouse IgG2a version of B4Mab-7 | FACS, WB, IHC | done |
| EphB6 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EphB6 mAb Eb6Mab-1 (mouse IgG1,kappa) |
specific for human EphB6; established by CBIS method; ref: clone T49-25 (BioLegend; Kd: 1.3 x 10^-8 M for DLD-1) | FACS | |||
| anti-EphB6 mAb Eb6Mab-2 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method Kd: 8.7 x 10^-9 M for CHO/hEphB6 |
FACS | |||
| anti-EphB6 mAb Eb6Mab-3 (mouse IgG1, kappa) |
specific for human EphB6; established by CBIS method ; Kd: 2.0 x 10^-9 M for DLD-1 | FACS, WB | in preparation (Kaneko et al) | done | |
| anti-EphB6 mAb Eb6Mab-4 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method< 3.6 x 10^-9 M for CHO/EphB6 |
FACS | |||
| anti-EphB6 mAb Eb6Mab-5 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-6 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method 3.7 x 10^-9 M for CHO/EphB6 |
FACS | |||
| anti-EphB6 mAb Eb6Mab-7 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method 3.0 x 10^-9 M for CHO/EphB6 |
FACS | |||
| anti-EphB6 mAb Eb6Mab-8 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method 2.5 x 10^-9 M for CHO/EphB6 |
FACS | |||
| anti-EphB6 mAb Eb6Mab-9 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-10 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-11 (mouse IgM, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-12 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-13 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-14 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-15 (mouse IgG1, lambda) |
specific for human EphB6 established by CBIS method 8.4 x 10^-9 M for CHO/EphB6 |
FACS | |||
| anti-EphB6 mAb Eb6Mab-16 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-17 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-18 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-19 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-20 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS, WB (weak) | |||
| anti-EphB6 mAb Eb6Mab-21 (mouse IgG2b, kappa) |
specific for human EphB6 established by CBIS method 7.5 x 10^-8 M for CHO/EphB6 |
FACS, WB (weak) | |||
| anti-EphB6 mAb Eb6Mab-22 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-23 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method Kd: 3.0 x 10^-8 M for CHO/hEphB6 |
FACS | |||
| anti-EphB6 mAb Eb6Mab-24 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method Kd: 3.8 x 10^-8 M for CHO/hEphB6 |
FACS | |||
| anti-EphB6 mAb Eb6Mab-25 (mouse IgG1 or G2b, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-26 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-29 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-30 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method 5.8 x 10^-9 M for CHO/EphB6 |
FACS | |||
| anti-EphB6 mAb Eb6Mab-31 (mouse IgG1, kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-32 (mouse IgG1 (G2b), kappa) |
specific for human EphB6 established by CBIS method |
FACS | |||
| anti-EphB6 mAb Eb6Mab-33 (mouse IgG1 (G2b), kappa) |
specific for human EphB6 established by CBIS method |
FACS |
| GM3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GM3 mAb (DH2-mG1, mouse IgG1, kappa) | specific for human GM3 | FACS | DH2 | done |
| GPC1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GPC1 mAb (G1Mab-1, mouse IgG2a, kappa) | specific for human GPC1 Kd: 4.5 x 10^-8 p.c.: 1019718 (R&D; Kd: 6.3 x 10^-8) |
FACS | done | ||
| anti-GPC1 mAb (G1Mab-2, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-3, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-4, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-5, mouse IgG2b, kappa) | specific for human GPC1 Kd: 3.5 x 10^-8 |
FACS, IHC | |||
| anti-GPC1 mAb (G1Mab-6, mouse IgG2b, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-7, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
| anti-GPC1 mAb (G1Mab-8, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
| anti-GPC1 mAb (G1Mab-9, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-10, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
| anti-GPC1 mAb (G1Mab-11, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-12, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-13, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
| anti-GPC1 mAb (G1Mab-14, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
| anti-GPC1 mAb (G1Mab-15, mouse IgG1) | specific for human GPC1 | FACS | |||
| anti-GPC1 mAb (G1Mab-16, mouse IgG2a, kappa) | specific for human GPC1 Kd: 1.4 x 10^-7 |
FACS, WB | |||
| anti-GPC1 mAb (G1Mab-17, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-18, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
| anti-GPC1 mAb (G1Mab-19, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-20, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-21, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-22, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
| anti-GPC1 mAb (G1Mab-23, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-24, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-25, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-26, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-27, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-28, mouse IgG1, kappa) | specific for human GPC1 Kd: 3.3 x 10^-8 |
FACS, WB, IHC | in preparation (Yamamoto et al) |
done | |
| anti-GPC1 mAb (G1Mab-29, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
| anti-GPC1 mAb (G1Mab-30, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-31, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
| anti-GPC1 mAb (G1Mab-32, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
| anti-GPC1 mAb (G1Mab-33, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-34, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-35, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-36, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-37, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-38, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB | |||
| anti-GPC1 mAb (G1Mab-39, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
| anti-GPC1 mAb (G1Mab-40, mouse IgG1, kappa) | specific for human GPC1 | FACS | |||
| anti-GPC1 mAb (G1Mab-41, mouse IgG1, kappa) | specific for human GPC1 | FACS, WB |
| GPC2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GPC2 mAb (G2Mab-1, mouse IgG2a, kappa) | specific for human GPC2; control: CST (Cat#90488); Kd: 1.3 x 10^-8 cell line: IMR-32 |
FACS | |||
| anti-GPC2 mAb (G2Mab-2, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
| anti-GPC2 mAb (G2Mab-3, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
| anti-GPC2 mAb (G2Mab-4, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
| anti-GPC2 mAb (G2Mab-5, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
| anti-GPC2 mAb (G2Mab-6, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
| anti-GPC2 mAb (G2Mab-7, mouse IgG1, kappa) | specific for human GPC2 Kd: 2.3 x 10^-8 |
FACS, WB, IHC | in preparation (Ishikawa et al) |
ongoing | |
| anti-GPC2 mAb (G2Mab-8, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
| anti-GPC2 mAb (G2Mab-9, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
| anti-GPC2 mAb (G2Mab-10, mouse IgG2b, kappa) | specific for human GPC2 | FACS | |||
| anti-GPC2 mAb (G2Mab-11, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
| anti-GPC2 mAb (G2Mab-12, mouse IgG1, kappa) | specific for human GPC2 | FACS | |||
| anti-GPC2 mAb (G2Mab-13, mouse IgG2a, kappa) | specific for human GPC2 | FACS | |||
| anti-GPC2 mAb (G2Mab-14, mouse IgG2a, kappa) | specific for human GPC2 | FACS | |||
| anti-GPC2 mAb (G2Mab-16, mouse IgG2a, kappa) | specific for human GPC2 | FACS | |||
| anti-GPC2 mAb (G2Mab-17, mouse IgG1, kappa) | specific for human GPC2 | FACS |
| GPC3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GPC3 mAb (G3Mab-4; mouse IgM, kappa) |
specific for human GPC3 | FACS, WB | in preparation | done | |
| anti-GPC3 mAb (G3Mab-7; mouse IgG1, kappa) |
specific for human GPC3 | FACS | done | ||
| anti-GPC3 mAb (G3Mab-8; mouse IgG2a, kappa) |
specific for human GPC3 | FACS | x | ||
| GPC3 | Character | Application | Ref | Gene cloning | Company |
| anti-GPC3 mAb (G3Mab-4-mG1; mouse IgG1, kappa) |
specific for human GPC3 | FACS, WB | done | ||
| anti-GPC3 mAb (G3Mab-4-mG2a; mouse IgG2a, kappa) |
specific for human GPC3 | FACS, WB | done | ||
| anti-GPC3 mAb (humG3Mab-4; human IgG1, kappa) |
specific for human GPC3 | FACS, WB | done | ||
| anti-GPC3 mAb (humG3Mab-4-scFv-hG1) |
specific for human GPC3 | FACS, WB | ongoing | ||
| anti-GPC3 mAb (humG3Mab-7; human IgG1, kappa) |
specific for human GPC3 | FACS | done | ||
| anti-GPC3 mAb (humG3Mab-7-scFv-Fc) |
specific for human GPC3 | FACS | ongoing |
| GPC4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GPC4 mAb (G4Mab-1, mouse IgM, kappa) | specific for human GPC4; pc: clone A21050B (BioLegend); endo (KYSE2710, HepG2, OUR-10, COLO201, COLO205, LS174T, MDA-MB-231, Lu65, 293FT) | FACS | in preparatin (Li et al) |
||
| anti-GPC4 mAb (G4Mab-2, mouse IgG1, kappa) | specific for human GPC4 | FACS | |||
| anti-GPC4 mAb (G4Mab-3, mouse IgG1, kappa) | specific for human GPC4 | FACS | |||
| anti-GPC4 mAb (G4Mab-4, mouse IgM, kappa) | specific for human GPC4 | FACS | |||
| anti-GPC4 mAb (G4Mab-5, mouse IgG1, kappa) | specific for human GPC4 | FACS | |||
| anti-GPC4 mAb (G4Mab-6, mouse IgG1, kappa) | specific for human GPC4 | FACS | |||
| anti-GPC4 mAb (G4Mab-7, mouse IgG1, kappa) | specific for human GPC4 | FACS | |||
| anti-GPC4 mAb (G4Mab-8, mouse IgG1, kappa) | specific for human GPC4 | FACS | |||
| anti-GPC4 mAb (G4Mab-9, mouse Ig) | specific for human GPC4 | FACS, WB | |||
| anti-GPC4 mAb (G4Mab-10, mouse Ig) | specific for human GPC4 | FACS |
| GPC5 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GPC5 mAb (G5Mab-1, mouse IgG1, kappa) | Kd: 9.93 x 10^-9 M; GPC5 expression in cancer cells (KYSE2710, Lu65, OUR-10, HepG2, MDA-MB-231) is very low; positive control: R&D, clone:297716 (Kd: 6.19 x 10^-9 M ) | FACS, WB | |||
| anti-GPC5 mAb (G5Mab-2, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
| anti-GPC5 mAb (G5Mab-3, mouse IgG2b, kappa) | specific for human GPC5 | FACS | |||
| anti-GPC5 mAb (G5Mab-4, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
| anti-GPC5 mAb (G5Mab-5, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
| anti-GPC5 mAb (G5Mab-6, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
| anti-GPC5 mAb (G5Mab-7, mouse IgG2b, kappa) | specific for human GPC5 | FACS | |||
| anti-GPC5 mAb (G5Mab-8, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
| anti-GPC5 mAb (G5Mab-9, mouse IgG1, kappa) | specific for human GPC5 Kd: 1.63 x 10^-8 M |
FACS, WB | |||
| anti-GPC5 mAb (G5Mab-10, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
| anti-GPC5 mAb (G5Mab-11, mouse IgG1, kappa) | specific for human GPC5 Kd: 1.01 x 10^-8 M |
FACS, WB | |||
| anti-GPC5 mAb (G5Mab-12, mouse IgG2b, kappa) | specific for human GPC5 | FACS | |||
| anti-GPC5 mAb (G5Mab-13, mouse IgG2b, kappa) | specific for human GPC5 | FACS, WB | |||
| anti-GPC5 mAb (G5Mab-14, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
| anti-GPC5 mAb (G5Mab-15, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
| anti-GPC5 mAb (G5Mab-16, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
| anti-GPC5 mAb (G5Mab-17, mouse IgG1, kappa) | specific for human GPC5 | FACS | |||
| anti-GPC5 mAb (G5Mab-18, mouse IgG1, kappa) | specific for human GPC5 | FACS |
| GPC6 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GPC6 mAb (G6Mab-1, mouse IgG1, kappa) | specific for human GPC6 | FACS | |||
| anti-GPC6 mAb (G6Mab-2, mouse IgG2a, kappa) | specific for human GPC6 | FACS | |||
| anti-GPC6 mAb (G6Mab-3, mouse IgM, kappa) | specific for human GPC6 | FACS | |||
| anti-GPC6 mAb (G6Mab-4, mouse IgG1, kappa) | specific for human GPC6 | FACS | |||
| anti-GPC6 mAb (G6Mab-5, mouse IgG1, kappa) | specific for human GPC6 | FACS | |||
| anti-GPC6 mAb (G6Mab-6, mouse IgG1, kappa) | specific for human GPC6 | FACS | |||
| anti-GPC6 mAb (G6Mab-7, mouse IgG1, kappa) | specific for human GPC6 | FACS | |||
| anti-GPC6 mAb (G6Mab-8, mouse IgG3, kappa) | specific for human GPC6 | FACS | |||
| anti-GPC6 mAb (G6Mab-9, mouse IgG1, kappa) | specific for human GPC6 | FACS | |||
| anti-GPC6 mAb (G6Mab-10, mouse IgG1, kappa) | specific for human GPC6 | FACS | |||
| anti-GPC6 mAb (G6Mab-11, mouse IgG1, kappa) | specific for human GPC6 | FACS | |||
| anti-GPC6 mAb (G6Mab-12, mouse IgG1, kappa) | specific for human GPC6 | FACS | |||
| anti-GPC6 mAb (G6Mab-13, mouse IgG1, kappa) | specific for human GPC6 | FACS, WB | in preparatin (Yamamoto et al) |
| TROP2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-TROP2 mAb (TrMab-6; mouse IgG2b, kappa) |
specific for human TROP2; (ref: TNBC) | IHC, WB, FACS |
TrMab-6 MCF7 TNBC |
done |
exbio |
| anti-TROP2 mAb (TrMab-29; mouse IgG1, kappa) |
specific for human TROP2 | IHC, WB, FACS | TrMab-29 | done | merck |
| anti-TROP2 mAb (Datopotamab; humanized IgG1, kappa) |
Humanized mAb for DS-1062/Dato-DXd (Daiichi-Sankyo) | FACS | done | ||
| anti-TROP2 mAb (Sacituzumab; humanized IgG1, kappa) |
Humanized mAb (Sacituzumab govitecan; Trodelvy) | FACS | done |
| HGF | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HGF mAb (t8E4; mouse IgG1, kappa) |
specific for active HGF | WB, IHC |
SREP IJMS |
done | Merck |
| anti-HGF mAb (t5A11; mouse IgG1, kappa) |
specific for HGF | WB, IHC |
SREP IJMS |
done | |
| anti-HGF mAb (t1E4; mouse IgG2b, kappa) |
specific for HGF | neutralization |
SREP |
done |
| Podocalyxin | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PODXL mAb (PcMab-47; mouse IgG1, kappa) |
specific for human PODXL | FACS, WB, IHC | PcMab-47 IHC_OSCC epitope |
done | APRO abcam exbio |
| Podocalyxin | Character | Application | Ref | Gene cloning | Company |
| anti-PODXL mAb (47-mG2a; mouse IgG2a, kappa) |
IgG2a version of PcMab-47; specific for human PODXL | FACS, WB, IHC; ADCC/CDC, antitumor activities | 47-mG2a IHC_LK IHC_EC |
done | |
| anti-PODXL mAb (47-mG2a-f; mouse IgG2a, kappa) |
core fucose-deficient IgG2a version of PcMab-47; specific for human PODXL | FACS, WB, IHC; ADCC/CDC, antitumor activities | 47-mG2a-f | done | |
| anti-PODXL mAb (chPcMab-47; human IgG1) |
specific for human PODXL | FACS, WB, IHC | chPcMab-47 | done |
| human podoplanin | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hPDPN mAb (NZ-1; rat IgG2a, lambda) |
specific for human PDPN | IP, IHC, WB, FACS (Review; patent) |
NZ-1 | done |
APRO |
| anti-hPDPN mAb (NZ-1.2; rat IgG2a) |
specific for human PDPN; the other clones: NZ-1.3(Thermo), NC-08 (BioLegend) | IP, IHC, WB, FACS | NZ-1.2 |
done | Merck,MBL,Novus, Zenogen,Wako |
| anti-hPDPN mAb (LpMab-2; mouse IgG1, kappa) | CasMab | IHC, WB, FACS | Cells2022 LpMab-2 patent |
done | |
| anti-hPDPN mAb (LpMab-3; mouse IgG1, kappa) | specific for human PDPN; epitope: Thr76 | IHC, WB, FACS | LpMab-3 epitope Structure |
done | MCP |
| anti-hPDPN mAb (LpMab-7 ;mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | LpMab-7 OS epitope |
done |
abcam MCP zenogen |
| anti-hPDPN mAb (LpMab-9; mouse IgG1, kappa) | specific for human PDPN; epitope: Thr25 | WB, FACS | LpMab-9 epitope |
done | MCP |
| anti-hPDPN mAb (LpMab-10; mouse IgG3, kappa) | specific for human PDPN; epitope: PLAG1 Thr34 | IHC, WB, FACS | LpMab-10 | done | |
| anti-hPDPN mAb (LpMab-12; mouse IgG1, kappa) | specific for human PDPN; epitope: PLAG3 Thr52 | IHC, WB, FACS | LpMab-12 | done |
APRO;
CST
Merck Hycult MCP, zenogen |
| anti-hPDPN mAb (LpMab-13; mouse IgG1, kappa) | specific for human PDPN; epitope: PLAG2-3 | IHC, WB, FACS | LpMab-13 | done | Merck Hycult |
| anti-hPDPN mAb (LpMab-16; mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | patent 2018-123699 | done | |
| anti-hPDPN mAb (LpMab-17; mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS press release |
LpMab-17 | done |
BD Merck Hycult |
| anti-hPDPN mAb (LpMab-19; mouse IgG2b, kappa) | specific for human PDPN; epitope: Thr76 | IHC, WB, FACS, ADCC/CDC | LpMab-19 | done | Merck |
| anti-hPDPN mAb (LpMab-21; mouse IgG2a, kappa) | specific for human PDPN; epitope: Thr76 | IHC, WB, FACS, ADCC/CDC press release |
Cells2022 LpMab-21 in vivo |
done |
Merck
BioLegend MCP |
| anti-hPDPN mAb (LpMab-23; mouse IgG1, kappa) | IHC, WB, FACS | YouTube LpMab-23 IHC patent |
done |
BD exbio |
|
| human podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-human PDPN mAb (NZ-8; human IgG1, kappa) |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP, IHC, WB, FACS | NZ-8 | done | |
| anti-human PDPN mAb (NZ-12; human IgG1, lambda) |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP, IHC, WB, FACS | NZ-12 RIT |
done | |
| anti-human PDPN mAb (NZ-16; human IgG1, lambda) |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP, IHC, WB, FACS | RIT | done | |
| anti-human PDPN mAb (NZ-27; human IgG1, lambda) |
specific for human PDPN; humanized mAb originated from NZ-1 | IP, IHC, WB, FACS |
NZ-27 CAR-T |
done | |
| anti-human PDPN mAb (chLpMab-7; human IgG1) | specific for human PDPN; mouse-human chimeric mAb originated from LpMab-7 | IHC, WB, FACS | chLpMab-7 | done |
| mouse podoplanin | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti mouse PDPN mAb (PMab-1; rat IgG2a, kappa) |
specific for mouse PDPN --> anti-human PDPN |
IHC, WB, FACS | PMab-1 PMab-1_LEC epitope |
done | abcam; MBL; Nov; Mer; BioL; BD |
| anti-mouse PDPN mAb (mPMab-1; mouse IgG2a,kappa) | specific for mouse PDPN | IHC, WB, FACS |
mPMab-1 |
done | |
| anti-mouse PDPN mAb (PMab-1-mG2a-f; mouse IgG2a,kappa) | specific for mouse PDPN | IHC, WB, FACS | done | ||
| rat podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-rat PDPN mAb (PMab-2; mouse IgG1, kappa) |
specific for rat PDPN | IHC, WB, FACS | PMab-2 PMab-2_epitope |
done |
abcam Merck BioLegend |
| rabbit podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-rabbit PDPN mAb (PMab-32; mouse IgG1, kappa) |
specific for rabbit PDPN | IHC, WB, FACS | PMab-32 epitope |
||
| dog podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-dog PDPN mAb (PMab-38; mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-38;
SCC melanoma epitope |
done |
zenogen Wako |
| anti-dog PDPN mAb (P38Bf; dog IgGB, kappa) |
core fucose-deficient type B of PMab-38 | IHC, WB, FACS |
P38Bf P38B_in vivo ADC |
done | |
| anti-dog PDPN mAb (PMab-48; mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-48 epitope |
done | zenogen |
| bovine podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-bovPDPN mAb (PMab-44; mouse IgG1, kappa) | specific for bovine PDPN | IHC, WB, FACS | PMab-44;
epitope goat; sheep; alpaca |
done | zenogen |
| cat podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-cat PDPN mAb (PMab-52; mouse IgM, kappa) |
specific for cat PDPN | IHC, WB, FACS | PMab-52;
epitope IHC-1; IHC-2 tiger PDPN |
done | zenogen |
| tiger podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-tiger PDPN mAb (PMab-231; mouse IgG2a, kappa) |
specific for tiger PDPN | IHC, WB, FACS | PMab-231 epitope; lion |
done | zenogen |
| tiger podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-tiger PDPN mAb (PMab-231-f; mouse IgG2a, kappa) |
defucosylation of PMab-231 | isotype control of mouse IgG2a in vivo |
250_in vivo | done | zenogen |
| horse podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-horse PDPN mAb (PMab-219; mouse IgG2a, kappa) |
specific for horse PDPN | WB, FACS, IHC | PMab-219 epitope |
done | zenogen |
| anti-horse PDPN mAb (PMab-202; mouse IgG1, kappa) |
specific for horse PDPN | WB, FACS | PMab-202 epitope |
done | zenogen |
| pig podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-pig PDPN mAb (PMab-213; mouse IgG2b, kappa) |
specific for pig PDPN | WB, FACS, IHC | PMab-213 epitope LEC |
done | zenogen |
| anti-pig PDPN mAb (PMab-210; mouse IgG1, kappa) |
specific for pig PDPN | WB, FACS, IHC | PMab-210 epitope |
done | zenogen |
| goat podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-goat PDPN mAb (PMab-235; mouse IgG1, kappa) | specific for goat PDPN | IHC, WB, FACS | PMab-235 epitope |
done | zenogen |
| alpaca podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-aPDPN mAb (PMab-225; mouse IgG2b, kappa) | specific for alpaca PDPN | IHC, WB, FACS |
PMab-225 epitope |
done | zenogen |
| Tas_devil podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-TasPDPN PDPN (PMab-233; mouse IgG1, kappa) | specific for Tasmanian devil PDPN | IHC, WB, FACS | PMab-233 epitope |
done | zenogen |
| bear podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-bear PDPN mAb (PMab-241; mouse IgG2b, kappa) |
specific for bear PDPN | IHC, WB, FACS | PMab-241 epitope |
||
| anti-bear PDPN mAb (PMab-247; mouse IgG1, kappa) |
specific for bear PDPN | IHC, WB, FACS | PMab-247 IHC epitope |
done | zenogen |
| whale podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-whale PDPN mAb (PMab-237; mouse IgG1, kappa) |
specific for whale PDPN | IHC, WB, FACS | PMab-237 IHC epitope |
done | zenogen |
| sheep podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-sheep PDPN mAb (PMab-256; mouse IgG1, kappa) |
specific for sheep PDPN | IHC, WB, FACS | PMab-256 epitope |
done | zenogen |
| anti-sheep PDPN mAb (PMab-253; mouse IgM, kappa) |
specific for sheept PDPN | IHC, WB, FACS | PMab-253 | done | |
| anti-sheep PDPN mAb (PMab-260; mouse IgM, kappa) |
specific for sheep PDPN | IHC, WB, FACS | PMab-260 | done | |
| sea lion podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-seaPDPN mAb (PMab-269; mouse IgG1, kappa) | specific for sea lion PDPN | IHC, WB, FACS | PMab-269 epitope Steller Sea Lion |
done | |
| elephant podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-elePDPN mAb (PMab-265; mouse IgM, kappa) | specific for elephant PDPN | FACS | PMab-265 | ||
| anti-elePDPN mAb (PMab-295; mouse IgG1, kappa) | specific for elephant PDPN | FACS, WB, IHC | PMab-295 epitope |
done |
Ab.antibody |
| ferret podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-ferret PDPN mAb (PMab-241; mouse IgG2b, kappa) |
anti-bear PDPN mAb crossreacts with ferret PDPN | IHC, WB, FACS | PMab-241 | ||
| anti-ferret PDPN mAb (PMab-292; mouse IgG1, kappa) |
specific for ferret PDPN | IHC, WB, FACS | PMab-292 epitope |
done |
Ab.antibody |
| anti-ferret PDPN mAb (PMab-293; mouse IgM, kappa) |
specific for ferret PDPN | FACS, WB | |||
| hamster podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-hamPDPN mAb (PMab-281; mouse IgG3, kappa) | specific for hamster PDPN | FACS, IHC | PMab-281
epitope |
done | |
| anti-hamPDPN mAb (281-mG2a; mouse IgG2a, kappa) | specific for hamster PDPN; IgG2a version of PMab-281 | FACS, IHC |
281-mG2a
epitope |
done | |
| anti-hamPDPN mAb (281-mG2a-f; mouse IgG2a, kappa) | defucocylated 281-mG2a | isotype control of mouse IgG2a in vivo |
H2Mab-214 H2Mab-77 |
done | |
| giraffe podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-girPDPN mAb (PMab-301; mouse IgG1, kappa) | specific for giraffe PDPN Kd: 1.3 x 10-8 M |
FACS, WB, IHC | PMab-301 | ||
| panda podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-panPDPN mAb (PMab-314; mouse IgG1, kappa) | specific for panda PDPN Kd: 1.3 x 10-8 M |
FACS, WB | PMab-314 | ||
| rhinoceros podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-rhiPDPN mAb (PMab-315; mouse IgG2a, kappa) | specific for rhinoceros PDPN | FACS, WB, IHC | Ubukata et al | ||
| anti-rhiPDPN mAb (PMab-324; mouse IgG2b, kappa) | specific for rhinoceros PDPN | FACS, WB, IHC | Fujisawa et al | ||
| hippopotamus podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-hipPDPN mAb (PMab-316; mouse IgG3(2b), kappa) | specific for hippopotamus PDPN | FACS, WB | Yamamoto et al | ||
| anti-hipPDPN mAb (PMab-317; mouse IgG1, kappa) | specific for hippopotamus PDPN | FACS, WB | |||
| anti-hipPDPN mAb (PMab-318; mouse IgG1, kappa) | specific for hippopotamus PDPN | FACS, WB | |||
| anti-hipPDPN mAb (PMab-319; mouse IgG3(2b), kappa) | specific for hippopotamus PDPN | FACS, WB | |||
| anti-hipPDPN mAb (PMab-320; mouse IgG1, kappa) | specific for hippopotamus PDPN | FACS, WB | |||
| anti-hipPDPN mAb (PMab-321; mouse IgM, kappa) | specific for hippopotamus PDPN | FACS | |||
| anti-hipPDPN mAb (PMab-322; mouse Ig2a, kappa) | specific for hippopotamus PDPN | FACS, WB | |||
| anti-hipPDPN mAb (PMab-323; mouse IgM, kappa) | specific for hippopotamus PDPN | FACS |
intracellular proteins
| ATRX | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-ATRX mAb (AMab-6; mouse IgG1, kappa) |
specific for human ATRX | IHC, WB | AMab-6 AMab-6_epitope AMab-6_IHC |
done | APRO abcam |
| DGK | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-DGKalpha mAb (DaMab-2; mouse IgG1, kappa) |
specifi for DGKalpha | ICC | DaMab-2 epitope |
done | |
| anti-DGKalpha mAb (Da2mG2a; mouse IgG2a, kappa) |
specifi for DGKalpha | ICC | done | ||
| anti-DGKalpha mAb (DaMab-8; mouse IgG1, kappa) |
specific for DGKalpha | IHC | DaMab-8 |
done | |
| anti-DGKalpha mAb (Da8mG2a; mouse IgG2a, kappa) |
specific for DGKalpha | ICC, IHC |
|
done | |
| anti-DGKgamma mAb (DgMab-6; mouse IgG1, kappa) |
specific for DGKgamma | ICC | DgMab-6 |
done | |
| anti-DGKalpha mAb (Dg6mG2a; mouse IgG2a, kappa) |
specifi for DGKgamma | ICC | done | ||
| anti-DGKzeta mAb (DzMab-1; rat IgG2b, kappa) |
specific for DGKzeta | ICC |
DzMab-1 epitope |
done | |
| anti-DGKzeta mAb (Dz1mG2a; mouse IgG2a, kappa) |
specific for DGKzeta | ICC | done | ||
| anti-DGKeta mAb (DhMab-1;mouse IgG2c, kappa) |
specific for DGKeta | IHC | DhMab-1 | done | |
| anti-DGKalpha mAb (Dh1mG2a; mouse IgG2a, kappa) |
specifi for DGKeata | ICC | done | ||
| anti-DGKeata mAb (DhMab-4; mouse IgG2b, kappa) |
specific for DGKeta | IHC |
DhMab-4 ICC |
done | |
| anti-DGKalpha mAb (Dh4mG2a; mouse IgG2a, kappa) |
specifi for DGKeata | ICC | done | ||
| anti-DGKdelta mAb (DdMab-1; mouse IgG2c, kappa) |
specific for DGKdeta | IHC | DdMab-1 | done | |
| anti-DGKalpha mAb (Dd1mG2a; mouse IgG2a, kappa) |
specifi for DGKdelta | ICC | done |
| IDH | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-IDH1-R132H mAb (HMab-1; mouse IgG1, kappa) | specific for IDH1-R132H | IHC, WB | HMab-1 | done | APRP;
Merck
MBL; IBL; Sigma |
| anti-IDH1-R132H mAb (HMab-2; mouse IgG1, kappa) | specific for IDH1-R132H | IHC, WB | HMab-2 | done | abcam |
| anti-IDH1-R132S mAb (SMab-1; mouse IgG1, kappa) | specific for IDH1-R132S | IHC, WB | SMab-1 | done |
APRO;
abcam
IBL; MBL Merck_Sigma |
| anti-IDH1-R132G mAb (GMab-r1; rat IgG2a, kappa) | specific for IDH1-R132G | IHC, WB | GMab-r1 | done |
abcam MBL |
| anti-IDH2-R172K mAb (KMab-1; rat IgG2b, kappa) | specific for IDH2-R172K | IHC, WB isotype control of rat IgG2b |
KMab-1 | done | abcam MBL |
| anti-IDH2-R172M mAb (MMab-1; rat IgG2b, kappa) | specific for IDH2-R172M | IHC, WB | MMab-1 | done |
abcam |
| anti-IDH2-R172W mAb (WMab-1; rat IgG2b, kappa) | specific for IDH2-R172W | IHC, WB | WMab-1 | done |
abcam MBL |
| anti-IDH2-R172S mAb (SMab-2; mouse IgG1, kappa) | specific for IDH2-R172S | IHC, WB | SMab-2 | done | abcam |
| anti-IDH1 mAb (RMab-3; mouse IgG1, kappa) | specific for IDH1 | IHC, WB | RMab-3 | done |
BD MBL |
| anti-IDH1 mAb(RcMab-1; rat IgG2a, kappa) | specific for IDH1 | IHC, WB isotype control of rat IgG2a |
RcMab-1 | done |
abcam CST MBL |
| anti-IDH2 mAb (RMab-22; mouse IgG2b, kappa) | specific for IDH2 | IHC, WB | RMab-22 | done | MBL |
| anti-IDH2 mAb (KrMab-3; mouse IgG2b, kappa) | specific for IDH2 | IHC, WB | KrMab-3 | done | CST BioLegend MBL |
| anti-mIDH1/2 mAb (MsMab-1; mouse IgG1, kappa) | specific for mutated IDH1/2 | IHC, WB (ref) |
TJEM Brain Tumor Pathol Cancer Med |
done | abcam Merck |
| anti-mIDH1/2 mAb (MsMab-2; rat IgG2a, kappa) | specific for mutated IDH1/2 | IHC, WB | MsMab-2 | done | MBL |
| TERT | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mTERT mAb (TmMab-1; rat IgG1, kappa) |
specific for mTERT | ELISA, WB isotype control of rat IgG1 |
done | ||
| anti-mTERT mAb (TmMab-2; rat IgG2a, kappa) |
specific for mTERT | ELISA isotype control of rat IgG2a |
done | ||
| anti-mTERT mAb (TmMab-3; rat IgG1, kappa) |
specific for mTERT | ELISA, WB isotype control of rat IgG1 |
done | ||
| anti-mTERT mAb (TmMab-4; rat IgG1, kappa) |
specific for mTERT | ELISA isotype control of rat IgG1 |
done | ||
| anti-hTERT mAb (TpMab-1; mouse IgG1, kappa) |
specific for phosphorylated threonine 249 of hTERT | IHC, WB, ELISA |
TpMab-1
(press) NCB |
done | |
| anti-hTERT mAb (TpMab-2; mouse IgG1, kappa) |
specific for phosphorylated threonine 249 of hTERT | IHC, WB, ELISA | done | ||
| anti-hTERT mAb (TpMab-3; mouse IgG1, kappa) |
specific for phosphorylated threonine 249 of hTERT | IHC, WB, ELISA |
TpMab-3 (press)
NCB |
done | Merck |
| anti-hTERT mAb (TpMab-35; mouse IgG1, kappa) |
specific for phosphorylated threonine 249 of hTERT | ICC, WB, ELISA | TpMab-35 | ||
| anti-hTERT mAb (TwMab-1; mouse IgG1, kappa) |
specific for hTERT | IHC, WB, ELISA | TwMab-1 | done | Merck |
| anti-hTERT mAb (TMab-6; mouse IgM, kappa) |
specific for hTERT | IHC |
TMab-6 TMab-6_epitope |
done |
Monoclonal antibodies for SARS-CoV-2
| SARS-CoV-2 (S1 RBD) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-1; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 319-338 aa RBD: Receptor binding domain |
ELISA,WB, IHC | done | ||
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-2; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, IHC, neutralization | |||
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-3; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 469-478 aa |
ELISA,WB, IHC, neutralization | |||
| anti SARS-CoV-2 S1-RBD mAb (CvMab-6; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, IHC, neutralization | CvMab-6 | done | |
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-7; mouse IgM, kappa) |
specific for SARS-CoV-2 S1-RBD epitope:459-478 aa |
ELISA, WB, IHC, neutralization | done | ||
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-13; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, IHC | done | ||
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-17; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, neutralization, IHC | |||
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-18; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, neutralization, IHC | |||
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-24; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, WB, IHC, neutralization | |||
| anti-SARS-CoV-2 S1-RBD mAb (CvMab-25; mouse IgG1, kappa) |
specific for SARS-CoV-2 S1-RBD epitope: 459-478 aa |
ELISA, IHC, WB |
| SARS-CoV-2 (S1 N terminus) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-SARS-CoV-2 mAb (CvMab-32; mouse IgG2b, kappa) |
specific for SARS-CoV-2 S1N terminus | ELISA, IHC, WB |
| SARS-CoV-2 (S2) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-SARS-CoV-2 mAb (CvMab-36; mouse IgG1, kappa) |
specific for SARS-CoV-2 S2 | ELISA, WB | |||
| anti-SARS-CoV-2 mAb (CvMab-62; mouse IgG1, kappa) |
specific for SARS-CoV-2 S2 | ELISA isotype control of mouse IgG1 |
CvMab-62 | done | |
| anti-SARS-CoV-2 mAb (CvMab-6-Fab; mouse Fab, kappa) |
specific for SARS-CoV-2 S2 | ELISA | done | ||
| anti-SARS-CoV-2 mAb (humCvMab-62; human IgG1, kappa) |
specific for SARS-CoV-2 S2 | ELISA isotype control of human IgG1 |
done |
| SARS-CoV-2 (bi-specific) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-SARS-CoV-2 mAb (CvMab-bis1) |
specific for SARS-CoV-2 S1+S2 bispecific mAb CvMab-6-H_CvM62scFv |
CvMab-bis1 | done | ||
| anti-SARS-CoV-2 mAb (CvMab-bis2) |
specific for SARS-CoV-2 S1+S2 bispecific mAb CvMab-6-L_CvM62scFv |
CvMab-bis2 | done | ||
| anti-SARS-CoV-2 mAb (CvMab-bis3) |
specific for SARS-CoV-2 S1+S2 bispecific mAb CvMab-62-H_CvM6scFv |
CvMab-bis3 | done | ||
| anti-SARS-CoV-2 mAb (CvMab-bis4) |
specific for SARS-CoV-2 S1+S2
bispecific mAb CvMab-62-L_CvM6scFv |
CvMab-bis4 | done | ||
| CvMab-62-H_Bebtelovimab-scFv (bispecific) |
specific for SARS-CoV-2 S1+S2 | Bebtelovimab | done | ||
| humCvMab-62-H_Bebtelovimab-scFv (bispecific) |
specific for SARS-CoV-2 S1+S2 | Bebtelovimab | done | ||
| CvMab-62-H_Cilgavimab-scFv (bispecific) |
specific for SARS-CoV-2 S1+S2 | done |
| SARS-CoV-2 (humanized) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| Bebtelovimab (human IgG1, lambda) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) |
Neutralization; weak activity for all variants | Bebtelovimab | done | |
| Cilgavimab (human IgG1, kappa) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) Cilgavimab plus tixagevimab (EVUSHELD) |
Neutralization; weak activity for BA.2; resistant for BA.4/5 | done | ||
| Casirivimab (human IgG1, kappa) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) Casirivimab plus imdevimab (Ronapreve) |
Neutralization; weak activity for Omicron | done | ||
| Bamlanivimab (human IgG1, kappa) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) |
Neutralization; no activity for Omicron | done | ||
| Bebtelovimab-scFv (scFv-Fc of human IgG1) |
specific for SARS-CoV-2 S1 | Bebtelovimab | done | ||
| Cilgavimab-scFv (scFv-Fc of human IgG1) |
specific for SARS-CoV-2 S1 | done |
| RdRP | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-RdRP mAb (RdMab-2; mouse IgG2a, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP; Immunogen: TRALTAESHVDTDLTKPYIC; distinguishes nsp12 of SARS-CoV-2 from that of SARS-CoV | ELISA, WB, IP, ICC | RdMab-2 | done | |
| anti-RdRP mAb (RdMab-13; mouse IgM, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP; Immunogen: TRALTAESHVDTDLTKPYIC; distinguishes nsp12 of SARS-CoV-2 from that of SARS-CoV |
ELISA, WB isotype control of mouse IgM |
RdMab-13 | done | |
| anti-RdRP mAb (RdMab-15; mouse IgG1, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP ; Immunogen: RHTFSNYQHEETIYNLLKDC |
ELISA, WB | RdMab-15 | ||
| anti-RdRP mAb (RdMab-16; mouse IgG1, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP ; Immunogen: RHTFSNYQHEETIYNLLKDC |
ELISA, WB | RdMab-16 | ||
| anti-RdRP mAb (RdMab-20; mouse IgG2b, kappa) |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP; Immunogen: TRALTAESHVDTDLTKPYIC; distinguishes nsp12 of SARS-CoV-2 from that of SARS-CoV |
ELISA, WB isotype control of mouse IgG2b |
RdMab-20 | done |
anti-Mpox monoclonal antibodies
| Mpox | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-Mpox mAb (MpMab-1, mouse IgG2b, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-2, mouse IgG1, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-3, mouse IgG1, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-4, mouse IgG1, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-5, mouse IgG1, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-6, mouse IgG1, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-7, mouse IgM, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-8, mouse IgG1, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-9, mouse IgG1, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-10, mouse IgG1, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-11, mouse IgG1, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-12, mouse IgG2b, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-13, mouse IgG2a, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-14, mouse IgM, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-15, mouse IgG2b, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-16, mouse IgG2b, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-17, mouse IgG1, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-18, mouse IgG2b, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-19, mouse IgG1, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-20, mouse IgG1, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-21, mouse IgG1, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-22, mouse IgG1, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-23, mouse IgG2a, kappa) |
specific for Mpox_A35R | ELISA | |||
| anti-Mpox mAb (MpMab-24, mouse IgG1, kappa) |
specific for Mpox_A35R | ELISA |
anti-dog protein monoclonal antibodies
| dog PDPN | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-dog PDPN mAb (PMab-38; mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-38;
SCC melanoma epitope |
done |
zenogen Wako |
| anti-dog PDPN mAb (P38Bf; dog IgGB, kappa) |
core fucose-deficient type B of PMab-38 | IHC, WB, FACS |
P38Bf P38B_in vivo ADC |
done | |
| anti-dog PDPN mAb (PMab-48; mouse IgG1, kappa) |
specific for dog PDPN | IHC, WB, FACS | PMab-48 epitope |
done | zenogen |
| dog EGFR | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (134-mG2a-f; mouse IgG2a, kappa) |
core fucose-deficient mouse IgG2a version of EMab-134; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | CHO/dEGFR Osteosarcoma Fibroblastic Mammary |
done | |
| anti-EGFR mAb (E134Bf; canine IgGB, kappa) |
core fucose-deficient canine IgGB version of EMab-134; specific for EGFR | FACS, WB, IHC, ADCC, CDC, antitumor activities | Mammary Fibro & Osteo |
done | |
| dog HER2 | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H77Bf; canine IgGB, kappa) |
core fucose-deficient canine IgGB version of H2Mab-77 | FACS, WB, IHC, ADCC/CDC, antitumor activities | H77Bf OS fibro |
done | |
| anti-HER2 mAb (H2Mab-41; mouse IgG2b, kappa) |
specific for HER2; crossreacts with dog HER2; domain-IV | FACS, antitumor activities | H2Mab-41
dogHER2 |
done | |
| EGFR-HER2 (bispecific) | Character | Application | Ref | Gene cloning | Company |
| anti-dog EGFR-dog HER2 mAb (E134B-H77scFv-f) |
bispecific mAb for EGFR and HER2 | FACS, WB, IHC, ADCC, CDC, antitumor activities | E134B-H77scFv-f | done | |
| dog PD-L1 | Character | Application | Ref | Gene cloning | Company |
| anti-dog PD-L1 mAb (L1Mab-347; mouse IgG1, kappa) |
specific for dog PD-L1 | FACS, IHC | done | ||
| anti-dog PD-L1 mAb (L1Mab-348; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-349; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-350; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-351; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-352; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | L1Mab-352 | done | |
| anti-dog PD-L1 mAb (L1Mab-353; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-354; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | L1Mab-354 | done | |
| anti-dog PD-L1 mAb (L1Mab-355; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb (L1Mab-356; mouse IgG1, kappa) |
specific for dog PD-L1 (intracellular domain) | ELISA |
anti-cat protein monoclonal antibodies
| cat MET | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-cat MET mAb (cMMab-1; mouse IgG1, kappa) |
specific for cat MET (No. 43) | FACS | done | ||
| anti-cat MET mAb (cMMab-2; mouse IgG1, kappa) |
specific for cat MET (No. 46) | FACS | done | ||
| anti-cat MET mAb (cMMab-3; mouse IgG1, kappa) |
specific for cat MET (No. 62) | FACS | done | ||
| anti-cat MET mAb (cMMab-4; mouse IgG1, kappa) |
specific for cat MET (No. 63) | FACS | done | ||
| anti-cat MET mAb (cMMab-5; mouse IgG1, kappa) |
specific for cat MET (No. 102) | FACS | done | ||
| anti-cat MET mAb (cMMab-6; mouse IgG1, kappa) |
specific for cat MET (No. 106) | FACS | done | ||
| anti-cat MET mAb (cMMab-7; mouse IgG1, kappa) |
specific for cat MET (No. 115) | FACS | done | ||
| anti-cat MET mAb (cMMab-8; mouse IgG1, kappa) |
specific for cat MET (No. 116) | FACS | done | ||
| anti-cat MET mAb (cMMab-9; mouse IgG1, kappa) |
specific for cat MET (No. 126) | FACS | done | ||
| anti-cat MET mAb (cMMab-10; mouse IgG1, kappa) |
specific for cat MET (No. 173) | FACS | done | ||
| anti-cat MET mAb (cMMab-11; mouse IgG1, kappa) |
specific for cat MET | FACS, agonistic | ongoing | ||
| anti-cat MET mAb (cMMab-12; mouse IgG2b, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-13; mouse IgG1, kappa) |
specific for cat MET | FACS, agonistic | ongoing | ||
| anti-cat MET mAb (cMMab-14; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-15; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-16; mouse IgG2a, kappa) |
specific for cat MET | FACS, agonistic | ongoing | ||
| anti-cat MET mAb (cMMab-17; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-18; mouse IgG1, kappa) |
specific for cat MET crossreact with human MET |
FACS | |||
| anti-cat MET mAb (cMMab-19; mouse IgG1, kappa) |
specific for cat MET crossreact with human MET |
FACS | |||
| anti-cat MET mAb (cMMab-20; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-21; mouse IgG2b, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-22; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-23; mouse IgG1, kappa) |
specific for cat MET crossreact with human MET |
FACS | |||
| anti-cat MET mAb (cMMab-24; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-25; mouse IgG1, kappa) |
specific for cat MET | FACS, agonistic | ongoing | ||
| anti-cat MET mAb (cMMab-26; mouse IgG1, kappa) |
specific for cat MET crossreact with human MET |
FACS | |||
| anti-cat MET mAb (cMMab-27; mouse IgG2b, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-28; mouse IgG2b, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-29; mouse IgG2a, kappa) |
specific for cat MET | FACS, agonistic | ongoing | ||
| anti-cat MET mAb (cMMab-30; mouse IgG1, kappa) |
specific for cat MET | FACS, agonistic | ongoing | ||
| anti-cat MET mAb (cMMab-31; mouse IgG1, kappa) |
specific for cat MET | FACS, agonistic | ongoing | ||
| anti-cat MET mAb (cMMab-32; mouse IgG2b, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-33; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-34; mouse IgG1, kappa) |
specific for cat MET | FACS, agonistic | |||
| anti-cat MET mAb (cMMab-35; mouse IgG2a, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-36; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-37; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-38; mouse IgG1, kappa) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-39; mouse Ig) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-40; mouse Ig) |
specific for cat MET | FACS | |||
| anti-cat MET mAb (cMMab-41; mouse Ig) |
specific for cat MET | FACS | |||
| cat podoplanin | Character | Application | Ref | Gene cloning | Company |
| anti-cat PDPN mAb (PMab-52; mouse IgM, kappa) |
specific for cat PDPN | IHC, WB, FACS | PMab-52;
epitope IHC-1; IHC-2 tiger PDPN |
done | zenogen |
| anti-tiger PDPN mAb (PMab-231; mouse IgG2a, kappa) |
crossreact with cat PDPN | IHC, WB, FACS | PMab-231 epitope; lion |
done | zenogen |
| anti-tiger PDPN mAb (PMab-231-f; mouse IgG2a, kappa) |
defucosylation of PMab-231 | isotype control of mouse IgG2a in vivo |
250_in vivo | done | zenogen |
CasMab
| PDPN | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hPDPN mAb (LpMab-2; mouse IgG1, kappa) | CasMab; patent |
IHC, WB, FACS | PDPN_review LpMab-2 |
done | restricted |
| anti-hPDPN mAb (LpMab-23; mouse IgG1, kappa) | IHC, WB, FACS | YouTube LpMab-23 IHC patent |
done | restricted | |
| anti-hPDPN mAb (PMab-117; rat IgM, kappa) | FACS |
YouTube PMab-117-mG2a Cells2022 |
done | restricted | |
| PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-human PDPN mAb(chLpMab-2; human IgG1, kappa) |
CasMab for human PDPN; mouse-human chimeric mAb originated from LpMab-2 | IP, IHC, WB, FACS | chLpMab-2 | done | restricted |
| anti-human PDPN mAb (chLpMab-23; human IgG1) | CasMab for human PDPN; mouse-human chimeric mAb originated from LpMab-23 | IHC, WB, FACS | YouTube chLpMab-23 |
done | restricted |
| anti-human PDPN mAb (humLpMab-23-f; human IgG1) | CasMab for human PDPN; humanized mAb originated from LpMab-23 | IHC, WB, FACS | YouTube humLpMab-23-f |
done | restricted |
| anti-human PDPN mAb (PMab-117-mG2a-f; mouse IgG2a) | CasMab for human PDPN; mouse IgG2a version of PMab-117 | FACS | PMab-117-mG2a | done | restricted |
| anti-human PDPN mAb (chPMab-117; human IgG1) | CasMab for human PDPN; mouse-human chimeric mAb originated from PMab-117 | FACS | YouTube | done | restricted |
| anti-human PDPN mAb (humPMab-117-f; human IgG1) | CasMab for human PDPN; humanized mAb originated from PMab-117 | FACS | YouTube | done | restricted |
| Podocalyxin | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PODXL mAb (PcMab-6; mouse IgG1, kappa) |
anti-PODXL CasMab
|
FACS | PcMab-6 patent |
done | restricted |
| anti-PODXL mAb (PcMab-60; mouse IgM, kappa) |
anti-PODXL CasMab | FACS | PcMab-60 epitope patent |
done | restricted |
| Podocalyxin | Character | Application | Ref | Gene cloning | Company |
| anti-PODXL mAb (PcMab-6-mG2a-f; mouse IgG2a) |
anti-PODXL CasMab; IgG2a version of PcMab-6
|
FACS, ADCC/CDC | PcMab-6-mG2a-f | done | restricted |
| anti-PODXL mAb (PcMab-6-hG1-f; human IgG1) |
anti-PODXL CasMab; human IgG1 version of PcMab-6 | FACS, ADCC/CDC | done | restricted | |
| anti-PODXL mAb (humPcMab-6-f; human IgG1) |
CasMab for PODXL; humanized mAb originated from PcMab-6 | FACS | humPcMab-6-f | done | restricted |
| anti-PODXL mAb (60-mG2a; mouse IgG2a, kappa) |
anti-PODXL CasMab; IgG2a version of PcMab-60 | FACS, ADCC/CDC | 60-mG2a | done | restricted |
| anti-PODXL mAb (60-mG2a-f; mouse IgG2a, kappa) |
anti-PODXL CasMab, core fucose-deficient IgG2a version of PcMab-60 | FACS, ADCC/CDC, antitumor activities | 60-mG2a-f | done | restricted |
| anti-PODXL mAb (PcMab-60-hG1-f; human IgG1) |
anti-PODXL CasMab; human IgG1 version of PcMab-60 | FACS, ADCC/CDC | done | restricted | |
| anti-PODXL mAb (humPcMab-60; human IgG1) |
anti-PODXL CasMab; humanized PcMab-60 | FACS, ADCC/CDC | done | restricted |
| CD44s | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44s mAb (C44Mab-1012; mouse IgM, kappa) |
Mab1 for CD44s (exon-6) cossreact with mouse CD44 |
FACS | done | ||
| anti-CD44s mAb (C44Mab-1075; mouse IgG2a, kappa) |
Mab2 for CD44s (exon-6) | FACS | done | ||
| anti-CD44s mAb (C44Mab-1095; mouse IgG1, kappa) |
Mab3 for CD44s (exon-6) | FACS | done | ||
| CD44s | Character | Application | Ref | Gene cloning | Company |
| anti-CD44s mAb (C44Mab-1012-mG1; mouse IgG1) |
Mab1 for CD44s (exon-6) | FACS | done | ||
| anti-CD44s mAb (C44Mab-1012-hG1; human IgG1) |
Mab1 for CD44s (exon-6) | FACS | done |
| CD44v3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44v3 mAb (C44Mab-1080; mouse IgG1, kappa) |
Mab6 for CD44v3 | FACS, WB, IHC | done | ||
| anti-CD44v3 mAb (C44Mab-1006; mouse IgG1, kappa) |
Mab11 for CD44v3 | FACS, WB, IHC | done | ||
| CD44v5 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v5 mAb (C44Mab-1088; mouse IgG1, kappa) |
Mab8 for CD44v5 | FACS, WB, IHC | done | ||
| anti-CD44v5 mAb (C44Mab-1003; mouse IgG1, kappa) |
Mab12 for CD44v5 | FACS, WB, IHC | done | ||
| CD44v6 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v6 mAb (C44Mab-1074; mouse IgM, kappa) |
V6CasMab-1 (IgM) for CD44v6 | FACS, WB, IHC | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1079; mouse IgG1, kappa) |
V6CasMab-2 for CD44v6 | FACS, WB, IHC | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1081; mouse IgG1, kappa) |
V6CasMab-3 for CD44v6 | FACS, WB, IHC | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1089; mouse IgM, kappa) |
V6CasMab-4 (IgM) for CD44v6 | FACS, WB, IHC | done | restricted | |
| anti-CD44v6 mAb (C44Mab-1092; mouse IgG3, kappa) |
V6CasMab-5 (IgG3) for CD44v6 | FACS, WB, IHC | done | restricted | |
| CD44v6 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v6 mAb (C44Mab-1074-mG1; mouse IgG1, kappa) |
V6CasMab-1 for CD44v6 | FACS, WB, IHC | restricted | ||
| anti-CD44v6 mAb (C44Mab-1089-mG1; mouse IgG1, kappa) |
V6CasMab-4 for CD44v6 | FACS, WB, IHC | restricted | ||
| anti-CD44v6 mAb (C44Mab-1092-mG1; mouse IgG1, kappa) |
V6CasMab-5 for CD44v6 | FACS, WB, IHC | restricted | ||
| CD44v7 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v7 mAb (C44Mab-1030; mouse IgM, kappa) |
Mab4 for CD44v7 | FACS, WB, IHC | done | ||
| anti-CD44v7 mAb (C44Mab-1048; mouse IgG1, kappa) |
Mab5 for CD44v7 | FACS, WB, IHC | done | ||
| anti-CD44v7 mAb (C44Mab-1034; mouse IgG1, kappa) |
Mab10 for CD44v7 | FACS, WB, IHC | done |
| EpCAM | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EpCAM mAb (EpMab-1147; mouse IgG1, kappa) |
Mab3 for EpCAM | FACS | done | ||
| anti-EpCAM mAb (EpMab-1007; mouse IgG1, kappa) |
Mab4 for EpCAM | FACS | done | ||
| anti-EpCAM mAb (EpMab-1013; mouse IgG1, kappa) |
Mab5 for EpCAM | FACS | done | ||
| anti-EpCAM mAb (EpMab-1022; mouse IgG1, kappa) |
Mab6 for EpCAM | FACS | done | ||
| anti-EpCAM mAb (EpMab-1069; mouse IgG1, kappa) |
Mab7 for EpCAM | FACS | done |
| TROP2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-TROP2 mAb (TrMab-1100; mouse IgG1, kappa) |
Mab1 for human TROP2 | FACS | done | ||
| anti-TROP2 mAb (TrMab-1148; mouse IgG1, kappa) |
Mab3 for human TROP2 | FACS | done | ||
| anti-TROP2 mAb (TrMab-1156; mouse IgG2b, kappa) |
Mab4 for human TROP2 | FACS | done |
| EGFR | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EGFR mAb (ECasMab-1001; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1002; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1003; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1004; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1005; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1006; mouse IgM, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1007; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1008; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1009; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1010; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1011; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1012; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1013; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1014; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1015; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1016; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1017; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1018; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1019; mouse IgG1, kappa) |
specific for EGFR | FACS | done | restricted | |
| anti-EGFR mAb (ECasMab-1020; mouse IgM, kappa) |
specific for EGFR | FACS | done | restricted |
| HER2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb (H2CasMab-1; mouse IgG1,kappa) |
H2Mab-214; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | H2Mab-214 | done | restricted |
| anti-HER2 mAb (H2CasMab-2; mouse IgG1,kappa) |
H2Mab-250; specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | H2Mab-250 250_in vivo 250_CDC |
done | restricted |
| anti-HER2 mAb (H2CasMab-3; mouse IgG3,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-4; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-5; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-6; mouse IgG2a,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-7; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-8; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-9; mouse IgG3,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-10; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-11; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-12; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-13; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-14; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-15; mouse IgG3,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-16; mouse IgG3,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-17; mouse IgG3,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-18; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-19; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-20; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-21; mouse IgG2a,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-22; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| anti-HER2 mAb (H2CasMab-23; mouse IgG1,kappa) |
specific for HER2; domain-IV PCT/JP2021/043538 |
FACS, WB, IHC | done | restricted | |
| HER2 | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H2Mab-250-mG2af; mouse IgG2a,kappa) |
H2CasMab-2; specific for HER2; domain-IV | FACS, WB, IHC | H2Mab-250 250_in vivo 250_CDC |
done | restricted |
| anti-HER2 mAb (H2Mab-250-hG1-f; human IgG1,kappa) |
H2CasMab-2; specific for HER2; domain-IV | ADCC/CDC; antitumor activities | 250_in vivo 250_CDC |
done | restricted |
| anti-HER2 mAb (humH2Mab-250-f; human IgG1,kappa) |
humanized H2Mab-250; H2CasMab-2; specific for HER2; domain-IV | ADCC/CDC; antitumor activities | done | restricted | |
| anti-HER2 mAb (H2Mab-214-mG2af; mouse IgG2a,kappa) |
H2CasMab-1; specific for HER2; domain-IV | FACS, WB, IHC | 214-mG2a-f | done | restricted |
| anti-HER2 mAb (H2Mab-214-hG1; human IgG1,kappa) |
H2CasMab-1; specific for HER2; domain-IV | FACS, WB, IHC | done | restricted |
| HER3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti HER3 mAb (H3Mab-1059; mouse IgG1,kappa) |
Mab1 for HER3 | FACS | done | ||
| anti HER3 mAb (H3Mab-1170; mouse IgG1,kappa) |
Mab2 for HER3 | FACS | done |
mCasMab
| mouse EGFR | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EGFR mAb (EMab-1302; rat IgG1, lambda) | crossreact with human EGFR; domain-I
semi-candidate |
FACS | |||
| anti-EGFR mAb (EMab-1303; rat IgM, kappa) | crossreact with human EGFR; domain-III
candidate |
FACS | done | ||
| anti-EGFR mAb (EMab-1304; rat IgG1, lambda) | crossreact with human EGFR; domain-I
semi-candidate |
FACS | |||
| mouse EGFR | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb (EMab-1303-mG1; mouse IgG1, kappa) | mouse IgG1 type of EMab-1303 | FACS | done | ||
| anti-EGFR mAb (EMab-1303-mG2a; mouse IgG2a, kappa) | mouse IgG2a type of EMab-1303 | FACS | done | ||
| anti-EGFR mAb (EMab-1303-hG1; human IgG1, kappa) | humna IgG1 type of EMab-1303 | FACS | done |
| mouse HER2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb (H2Mab-1301; rat IgG2a, lambda) |
specific for mouse HER2; cross-react with HER2 (human; domiain-I); does not cross-react with dog HER2 | FACS | done | ||
| anti-HER2 mAb (H2Mab-1316; rat IgG2a, kappa) |
specific for mouse HER2; cross-react with HER2 (human; domiain-I); does not cross-react with dog HER2 | FACS | done | ||
| anti-HER2 mAb (H2Mab-1319; rat IgG2a, kappa) |
specific for mouse HER2; cross-react with HER2 (human; domiain-I); does not cross-react with dog HER2 | FACS | done | ||
| mouse HER2 (CD340) | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H2Mab-1301-hG1 ;human IgG1,kappa) |
hIgG1 version of H2Mab-1301;
cross-react with HER2 (human) |
FACS | done | ||
| anti-HER2 mAb (H2Mab-1316-hG1 ;human IgG1,kappa) |
hIgG1 version of H2Mab-1316; cross-react with HER2 (human) |
FACS | done | ||
| anti-HER2 mAb (H2Mab-1319-hG1 ;human IgG1,kappa) |
hIgG1 version of H2Mab-1319; cross-react with HER2 (human) |
FACS | done |
CAR-T
| CD19 original | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD19 mAb (C19Mab-2; mouse IgG1,kappa) | specific for CD19; CBIS method; LN229/CD19 immunization | FACS | done | CD19 humanized | Character | Application | Ref | Gene cloning | Company |
| anti-CD19 mAb (humC19Mab-2; human IgG1,kappa) | specific for CD19 | FACS | done | CD19 scFv | Character | Application | Ref | Gene cloning | Company |
| anti-CD19 mAb (humC19Mab-2 -scFv) |
scFv of humanized C19Mab-2 | FACS | done |
| GPC3 original | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-GPC3 mAb (G3Mab-1; mouse IgG1, kappa) |
specific for human GPC3 ref: abcam |
FACS | done | ||
| anti-GPC3 mAb (G3Mab-2; mouse IgM, kappa) |
specific for human GPC3 | FACS, WB | done | ||
| anti-GPC3 mAb (G3Mab-3; mouse IgM, kappa) |
specific for human GPC3 | FACS, WB | done | ||
| GPC3 humanized | Character | Application | Ref | Gene cloning | Company |
| anti-GPC3 mAb (humG3Mab-1; human IgG1, kappa) |
specific for human GPC3 | FACS | done | ||
| anti-GPC3 mAb (humG3Mab-2; human IgG1, kappa) |
specific for human GPC3 | FACS | done | ||
| anti-GPC3 mAb (humG3Mab-3; human IgG1, kappa) |
specific for human GPC3 | FACS | done | ||
| GPC3 scFv | Character | Application | Ref | Gene cloning | Company |
| anti-GPC3 mAb (humG3Mab-1-scFv-Fc) |
specific for human GPC3 | CAR-T | done | ||
| anti-GPC3 mAb (humG3Mab-2-scFv-Fc) |
specific for human GPC3 | CAR-T | done | ||
| anti-GPC3 mAb (humG3Mab-3-scFv-Fc) |
specific for human GPC3 | CAR-T | done |
| HER2 original | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb (H2CasMab-2; mouse IgG1,kappa) |
H2Mab-250; specific for HER2; domain-IV | FACS, WB, IHC | H2Mab-250 250_in vivo 250_CDC |
done | restricted |
| HER2 scFv | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb (H2CasMab-2-scFv-Fc) |
specific for HER2; domain-IV |
CART | FT825 | done | restricted |
| PDPN original | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hPDPN mAb (LpMab-2; mouse IgG1, kappa) | CasMab | IHC, WB, FACS | Cells2022 LpMab-2 patent |
done | restricted |
| anti-hPDPN mAb (LpMab-23; mouse IgG1, kappa) | CasMab
|
IHC, WB, FACS | YouTube LpMab-23 IHC patent |
done | restricted |
| anti-hPDPN mAb (PMab-117; rat IgM, kappa) | CasMab | FACS | YouTube PMab-117-mG2a Cells2022 patent |
done | restricted |
| PDPN humanized | Character | Application | Ref | Gene cloning | Company |
| anti-hPDPN mAb (humLpMab-23; human IgG1, kappa) |
|
IHC, WB, FACS | YouTube humLpMab-23-f |
done | restricted |
| anti-hPDPN mAb (humPMab-117; human IgG1, kappa) | FACS | YouTube | done | restricted | |
| PDPN scFv | Character | Application | Ref | Gene cloning | Company |
| anti-hPDPN mAb (LpMab-2-scFv-Fc) | CasMab for human PDPN; scFv originated from LpMab-2 |
CART | LpMab-2-CART | done | restricted |
| anti-hPDPN mAb (humLpMab-23-scFv-Fc) | CasMab for human PDPN; scFv originated from LpMab-23 |
CART | YouTube | done | restricted |
| anti-hPDPN mAb (humPMab-117-scFv-Fc) |
CasMab for human PDPN; scFv originated from PMab-117 |
CART | YouTube | done | restricted |
| Podocalyxin original | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PODXL mAb (PcMab-6; mouse IgG1, kappa) |
anti-PODXL CasMab | FACS | PcMab-6 patent |
done | restricted |
| Podocalyxin humanized | Character | Application | Ref | Gene cloning | Company |
| anti-PODXL mAb (humPcMab-6; human IgG1, kappa) |
anti-PODXL CasMab | FACS | humPcMab-6-f | done | restricted |
| Podocalyxin scFv | Character | Application | Ref | Gene cloning | Company |
| anti-hPDPN mAb (humPcMab-6-scFv; scFv) | CasMab; scFv originated from PcMab-6 | CART | accept | done | restricted |
Company (clone) --> mAb list (target)
Abcam
AMab-6/ C44Mab-5/ CMab-43/ EMab-134/ GMab-r1/ H2Mab-139/ HMab-2/ KMab-1/ LpMab-7/ MMab-1/ MsMab-1/ PMab-1/ PcMab-47/ RcMab-1/ SMab-1/ WMab-1
Absolute antibody
PMab-1/ PMab-2/ PMab-292/ PMab-295
APRO (PFI)
AMab-6/ HisMab-1/ HMab-1/ HMab-2/ LpMab-12/ NZ-1/ PMab-1/ PMab-2/ PMab-44/ PcMab-47/ TMab-2
BD
C2Mab-6/ C3Mab-4 (C3Mab-6, C3Mab-7)/ C6Mab-9/ C39Mab-1 (C39Mab-2)/ C44Mab-6/ C44Mab-9/ Cx6Mab-1/ CMab-43/ H2Mab-303 (H2Mab-304, H2Mab-307)/ EMab-134/ EMab-300/ LpMab-17/ LpMab-23/ NZ-1/ PMab-1/ RMab-3/ TgMab-2
BioLegend
C20Mab-60/ C44Mab-5/ KrMab-3/ LpMab-21/ PMab-1/ PMab-2/ YM-2
CST
C44Mab-3/ C44Mab-9/ C44Mab-108/ KrMab-3/ LpMab-12/ RcMab-1
Exbio
C9Mab-1/ H3Mab-17/ LpMab-23/ PcMab-47/ TrMab-6
FUJIFILM WAKO
AMab-6/ CMab-43/ C44Mab-1/ C44Mab-3/ C44Mab-6/ C44Mab-9/ C44Mab-18/ C44Mab-34/ C44Mab-46/ C44Mab-94/ C44Mab-108/ EMab-134/ HMab-1/ HMab-2/ MsMab-1/ NZ-1/ NZ-1.2/ PMab-1/ PMab-38/ PcMab-47/ RMab-22/ SMab-1/ TMab-6
Hycult
LpMab-12/ LpMab-13/ LpMab-17
IBL
HMab-1/ SMab-1
MCP
LpMab-3/ LpMab-7/ LpMab-9/ LpMab-12/ LpMab-21
MBL
GMab-r1/ HMab-1/ KMab-1/ KrMab-3/ MMab-1/ MsMab-2/ NZ-1.2/ PMab-1/ RcMab-1/ RMab-3/ SMab-1/ WMab-1
Merck
C8Mab-2/ C44Mab-3/ C44Mab-9/ C44Mab-108/ EpMab-16/ G4B1/ HMab-1/ LpMab-12/ LpMab-13/ LpMab-17/ LpMab-21/ MsMab-1/ NZ-1.2/ PMab-1/ PMab-2/ RMab-3/ RMab-22/ SMab-1/ t8E4/ TpMab-3/ TrMab-29/ TwMab-1
Novus
NZ-1.2/ PMab-1
Zenogen
LpMab-7/ LpMab-12/ PMab-38/ PMab-44/ PMab-48/ PMab-52/ PMab-202/ PMab-210/ PMab-213/ PMab-219/ PMab-225/ PMab-231/ PMab-233/ PMab-235/ PMab-237/ PMab-247/ PMab-256/ NZ-1.2
Back to list
Abcam
AMab-6/ C44Mab-5/ CMab-43/ EMab-134/ GMab-r1/ H2Mab-139/ HMab-2/ KMab-1/ LpMab-7/ MMab-1/ MsMab-1/ PMab-1/ PcMab-47/ RcMab-1/ SMab-1/ WMab-1
Absolute antibody
PMab-1/ PMab-2/ PMab-292/ PMab-295
APRO (PFI)
AMab-6/ HisMab-1/ HMab-1/ HMab-2/ LpMab-12/ NZ-1/ PMab-1/ PMab-2/ PMab-44/ PcMab-47/ TMab-2
BD
C2Mab-6/ C3Mab-4 (C3Mab-6, C3Mab-7)/ C6Mab-9/ C39Mab-1 (C39Mab-2)/ C44Mab-6/ C44Mab-9/ Cx6Mab-1/ CMab-43/ H2Mab-303 (H2Mab-304, H2Mab-307)/ EMab-134/ EMab-300/ LpMab-17/ LpMab-23/ NZ-1/ PMab-1/ RMab-3/ TgMab-2
BioLegend
C20Mab-60/ C44Mab-5/ KrMab-3/ LpMab-21/ PMab-1/ PMab-2/ YM-2
CST
C44Mab-3/ C44Mab-9/ C44Mab-108/ KrMab-3/ LpMab-12/ RcMab-1
Exbio
C9Mab-1/ H3Mab-17/ LpMab-23/ PcMab-47/ TrMab-6
FUJIFILM WAKO
AMab-6/ CMab-43/ C44Mab-1/ C44Mab-3/ C44Mab-6/ C44Mab-9/ C44Mab-18/ C44Mab-34/ C44Mab-46/ C44Mab-94/ C44Mab-108/ EMab-134/ HMab-1/ HMab-2/ MsMab-1/ NZ-1/ NZ-1.2/ PMab-1/ PMab-38/ PcMab-47/ RMab-22/ SMab-1/ TMab-6
Hycult
LpMab-12/ LpMab-13/ LpMab-17
IBL
HMab-1/ SMab-1
MCP
LpMab-3/ LpMab-7/ LpMab-9/ LpMab-12/ LpMab-21
MBL
GMab-r1/ HMab-1/ KMab-1/ KrMab-3/ MMab-1/ MsMab-2/ NZ-1.2/ PMab-1/ RcMab-1/ RMab-3/ SMab-1/ WMab-1
Merck
C8Mab-2/ C44Mab-3/ C44Mab-9/ C44Mab-108/ EpMab-16/ G4B1/ HMab-1/ LpMab-12/ LpMab-13/ LpMab-17/ LpMab-21/ MsMab-1/ NZ-1.2/ PMab-1/ PMab-2/ RMab-3/ RMab-22/ SMab-1/ t8E4/ TpMab-3/ TrMab-29/ TwMab-1
Novus
NZ-1.2/ PMab-1
Zenogen
LpMab-7/ LpMab-12/ PMab-38/ PMab-44/ PMab-48/ PMab-52/ PMab-202/ PMab-210/ PMab-213/ PMab-219/ PMab-225/ PMab-231/ PMab-233/ PMab-235/ PMab-237/ PMab-247/ PMab-256/ NZ-1.2